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ABSTRACT 
MECHANISTIC STUDIES OF GUANINE-RICH OLIGONUCLEOTIDES 
Allicia C. Girvan 
May 2006 
Guanine-rich oligonucleotides (GROs) are being developed as a novel anticancer 
agents. GROs exhibit potent antiproliferative properties against several malignant cell 
lines and in established in vivo tumor models. In a recent Phase I clinical trial for patients 
with advanced cancer, one of these GROs was found to have promising signs of clinical 
activity with no serious side effects. It has been shown that the activity of GROs requires 
the fonnation of a G-quartet structure, and their activity correlates with its ability to bind 
to a specific complex of proteins. One important GRO-binding protein that has been 
previously identified is nucleolin, a multifunctional protein that is expressed at high 
levels in cancer cells. In this report, we investigate the novel mechanism of GRO activity 
by identifying the proteins that bind to an active GRO with use of mass spectrometry. 
Fourteen nuclear proteins and three cytoplasmic proteins were identified as associating 
with the active GRO, all of which vary in cellular functions described in the present 
study. The identified GRO-associated proteins include a protein known as NEMO (NF-
KB essential modulator). NF-KB transcription regulates the expression of genes involved 
in cellular processes such as cell growth, differentiation, and apoptosis. NF-KB signaling 
is often deregulated in cancer cells, and NEMO is a regulatory component ofthe cascade. 
v 
We demonstrate here that GROs bind to NEMO and nuc1eolin inside the cell, inhibit NF-
KB transcription, and prevent phosphorylation of the NF-KB signaling cascade in 
response to TNFu. To further investigate the mechanism of GROs, we utilized global 
expression technology to determine the effects of GROs on the entire cell. Microarray 
gene expression analysis revealed the alteration of 63 genes after 2 hours of treatment 
with GRO, and 238 genes after 18 hours of treatment with GRO revealing multiple 
biological systems affected. The data presented in this report reveals important features 
of the effects of GROs on the cell which gives insight into the anti proliferative 
mechanism of the novel anticancer agent. 
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CHAPTER I 
BACKGROUND AND INTRODUCTION 
OLIGONUCLEOTIDE THERAPEUTICS 
Oligonucleotides are short nucleic acid chains of DNA or RNA up to 100 
nucleotides long. Although synthesized chemically, oligonucleotides are identical to 
naturally occurring nucleic acid sequences with a sugar-phosphate backbone and either 
purine or pyrimidine base attached to the sugar ring. Because of their structural 
similarity, oligonucleotides mimic the interactions of nucleic acids found in nature. They 
have the potential to recognize unique DNA or RNA by sequence specific hybridization 
or bind to proteins by recognizing a specitIc sequence or shape (reviewed in [1 D. 
Therapeutic strategies based on the use of oligonucleotides have become very 
attractive due to their apparent high target specitIcity and tew toxic side etlects [1, 2]. 
Oligonucleotide therapy is now being developed as treatment in a broad range of diseases 
such as cancer, genetic disorders, coronary disease, inflammatory disease, and viral 
intections including HlV, intluenza, and hepatitis [1-3]. There are several different 
strategies utilizing oligonucleotides in therapy such as triplex formation, antisense, 
siRNA, and aptamer oligonucleotides. 
1 
Triplex forming oligonucleotides 
Triplex forming oligonucleotides (TFOs) are molecules that bind in a sequence-
specific manner to duplex DNA creating a third strand. TFOs bind in the major grove of 
duplex DNA on polypurine/polypyrimidine tracts. Upon binding, TFOs can alter gene 
expression by physically blocking the target site and inhibiting transcription initiation or 
transcription elongation (Figure lA). Another mechanism by which TFOs modify gene 
expression is by site-directed mutagenesis. TFOs can either deliver a mutagen-causing 
agent, or cause mutagenesis within the binding site in the absence of a mutagen (Figure 
IB). TFOs can also function by stimulating recombination in the target sequence by 
inducing DNA repair in tandem homologous regions or by introducing a homologous 
donor to the target sequence (Figure 1 C) [4-6]. 
Antisense oligonucleotides 
Antisense oligonucleotides (ASOs) refer to oligonucleotides designed specifically 
to bind to target mRNA and inhibit the expression of the target gene. Once the ASO 
hybridizes to the complementary mRNA strand, gene expression can be modified by 
preventing the formation of ribosomal complexes, thus inhibiting the tmnslation of the 
target protein (Figure 2). ASOs can also function by binding to the target mRNA, and 
activating RNase H which leads to the degradation of the target mRNA, and inhibiting 
the expression of the gene of interest (Figure 2) [7-9] .. 
2 
Figure 1: Mechanisms of Triplex forming oligonucleotides. 
(A) Blocking of transcription by interfering with transcription factors or elongation; 
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Figure 2: Mechanisms of antisense oligonucleotides. 
Antisense oligonucleotides inhibit translation by either blocking ribosome formation or 
activating RNase H [7]. 
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Small interfering RNA 
Small interfering RNA (siRNA) refers to small double-stranded RNA nucleotides 
designed to lead to the degradation of complementary mRNA resulting in down 
regulation of the gene of interest. The mechanism of siRNA begins with the production 
of double-stranded RNA complementary to the target mRNA. This double-stranded 
RNA is then cleaved by the enzyme Dicer into smaller siRNA fragments that are then 
unwound by a helicase. One strand of siRNA is then incorporated into RNA-induced 
silencing complex (RISe). Subsequently, lUSC IS guided to the target rnRNA for 
cleavage, resulting in reduced translation of the target mRNA (Figure 3) [7]. 
Aptamer oligonucleotides 
Aptamers are RNA or DNA oligonucleotides that can bind with high specificity to 
a wide range of target molecules including amino acids, antibiotics, proteins, and nucleic 
acids. Aptamers also bind to their target molecules with very high affinity due to their 
ability to fold upon binding to the target molecule. This aUows the incorporation of the 
nucleic acid into the structure of the molecule such as a protein. Upon binding to the 
target, apatmers subsequently modulate is activity [10-13]. 
GUANINE-RICH OLIGONUCLETIDES AND G-QUARTETS 
Nucleic acids rich in guanine are capable of forming four-stranded structures that 
are stabiHzed by G-quartets. G-quartets contain tour coplanar guanines stabilized by 
Hoogsteen hydrogen bonds with a monovalent cation in the center (Figure 4). These G-
7 
Figure 3: Mechanism of small interfering RNA. 
Doubie stranded RNA is cleaved by Dicer into siRNAs. Heiicases unwind the siRNA 
and then the siRNA is incorporated into RISe, which guides the siRNA to its target 
mRNA for cleavage [7]. 
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Figure 4: Schematic diagram of the G-quartet showing four guanines linked by 
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quartets are capable of hydrophobic stacking that increases the stability of the structure 
wIth increasing number of stacks. Based on the number of single-stranded 
oligonucleotides involved in formation of the G-quartets, there are several different 
strand configurations possible as seen in Figure 5. G-quartets can contain four single-
stranded oligonucleotides that form a tetraplex structure (Figure 5A). Two strand 
dimerization can occur with hairpin loops along the edge (Figure 58) or diagonally 
(Figure 5C). A monomer structure can also occur with the single oligonucleotide strand 
t'olding upon itself (¥igure sf) [14, 15]. 
It is now widely believed that G-quartets are involved in regulating diverse 
biological fimctions. Sequences capable 01' forming the G-quartet motif have been 
identified in telomeres [16], which are specialized sequences at the ends of chromosomes. 
The enzyme telomerase adds the telomeric repeat sequence onto chromosome ends. It 
has been shown that 85-90% of aU human cancers are positive for telomerase, and most 
somatic cells appear to lack detectable levels of the enzyme [17]. Recently, there has 
been intense interest in telomeres and G-quartets as a novel target for cancer therapy [18]. 
Other sequences capable of forming G-quartets have been identified in vitro. 
There has been particular interest in sequences such as the c-myc promoter [19], the HIF-
la promoter [20], the c-kit promoter [21], the fragile X repeat sequence [22], and the 
Cystatin B promoter, which has been implicated in epilepsy [23]. Guanine-rich strands 
have also been reported in the human insulin gene [24], immunoglobulin switch regions 
[25], and 1-ltVl RNA [~6j. 
12 
Figure 5: Schematic representing different G-quartet motifs. 
(A) Four single-stranded oiigonucieotides forming a tetrapiex; (B) a dimer of 
oligonucleotides with edgewise loops; (C) a dimer of oligonucleotides with diagonal 
loops; and (D) a monomer. 
13 
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G-quartet motifs most likely bind to specific proteins by the aptamer mechanism, 
which involves shape-specific recognition of the protein. A number of proteins that 
interact specifically with G-quartets have been previously identified. Nucleolin has been 
reported to bind to G-quartet sequences in immunoglobin switch regions [25], telomeres 
[27], ribosomal genes (28], and the c-myc promoter [29], although its function in (J-
quartet binding is not yet understood. Other proteins capable of binding to G-quartets 
include helicases implicated Bloom's [30] and Werner's [31] syndromes, the 
Saccharomyces cerevisiae protein CdCI3p P1], and the zinc t1nger protein Gql P3]. 
PROPERTIES OF GUANINE-RICH OLIGONUCLEOTIDES 
Guanine-rich oiigonuc1eotides (GROs) are a class of G-quartet forming 
oligonucleotides that exhibit potent growth inhibitory effects against many malignant 
cells lines [34-37]. Figure 6 (A-C) shows the antiproliterative activity of GRas against 
breast cancer celts in culture (tor ali GRO sequences see table 1). the active GRO 
(GR029A) almost completely inhibits the growth of hormone-dependent (MCF7) and 
hormone-independent (MDA-MB-231) breast cancer cell lines, whereas the control 
olIgonuc1eotide (GROI513) has Httte efi"'ect. this growth inhibition is also seen in an in 
vivo model with mice. Figure 6D shows that AGROlOO (a truncated version of 
GR029A) can completely inhibit the growth of human DU145 prostate tumor xenograft:s 
in nude mice, whereas the control oligonucleotide shows tittle effect 
These results lead to a Phase I clinical trial in patients with advanced cancer. 
Seventeen patients received Auf{Ol()() and results indicated that AuftOlOO had little 
15 
Table 1: Sequences and antiproliferative activities of GROs. 
16 
Antiproliferative 
GRO Sequence activity 
GR029A 5' -TTTGGTGGTGGTGGTIGTGGTGGTGGTGG active 
GR015B 5' -TIGGGGGGGGTGGGT inactive 
AGR0100 5' -GGTGGTGGTGGTTGTGGTGGTGGTGG active 
CR026 5' .,CCTCCTCCTCCTTCTCCTCCTCCTCC inactive 
TEL 5' -TIAGGGTIAGGGTIAGGGTIAGG inactive 
17 
Figure 6: Antitumor activity of GROs. 
(A and B) GR029A inhibits the growth ofMDA-MB-231 and MCF'1 breast cancer cells 
in culture (cells were treated as described in [31]); (C) dose-dependent antiproliferative 
effects of GR029A (single-dose) against MDA-MB-231; (D) activity of AGROlOO 
against established humor tumor xenografts (oU145) in nude mice at dose equivalent to 
1 or 5 mglkg (mpk). Tumor volume was measured using calipers and values shown are 
the mean for 6 animals. Error bars are not shown but differences were statistically 
signit1cant for 5 mpk (p=.044; p=.08L for 1 mpk). 
18 
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toxicity and no serious side effects [38]. An analysis of the efficacy of the drug revealed 
seven patients showed disease stabilization lasting between ~ and i 5 months. 
Additionally, one patient exhibited almost complete remission of disease with his tumor 
regressing from 19 cm to less than 1 cm, and the regression continued for more than 16 
months [3~l These results demonstrate AflIt010b as a promising novel anti-cancer 
agent. 
The antiproliferative activity of GROs apparently has a novel mechanism of action that is 
completely different from conventional chemotherapeutic drugs. Upon treatment with 
GRO, cancer cells exhibit S phase cell cycle arrest, DNA replication inhibition, and cell 
death [35]. From the sequence of active GROs, it is clear that they are not working by a 
hybridization-dependent mechanism such as triplex, antisense, or siRNA. Instead, it is 
thought that they function as aptamers by binding to specific proteins via shape-specific 
recognition [34-37]. A structural analysis of GROs revealed that the antiproliferative 
activity of 6f{Os requires the formation of the 6-quartet motif. The analysis also 
revealed that the growth inhibitory activity of GROs positively correlates with their 
ability to bind to a complex of proteins [37], one of which has been previously identified 
as nucleolin [34]. 
Nucleolin is a multifunctional 11O-kDa phosphoprotein that has been implicated 
in a variety of biological processes such as cell growth and proliferation [4()-4~], 
ribosome biogenesis [40, 43], DNA replication [44], cytokinesis and nuclear division 
[45], and apoptosis [46,47]. Nucleolin is generally considered a predominantly nucleolar 
20 
protein, however, there have been numerous reports demonstrating that nueleolin can also 
be present in the nucleoplasm, cytoplasm, and on the celt surface [34, 48-53]' 
Futhermore, the redistribution of nueleolin has been shown in response to stimuli such as 
heat shock [44, 54], T-cell activation [55], mitosis [56], treatment with cyelin-dependent 
kinase inhibitor [57], and viral infection [58-60]. It is now wide1y believed that nucleoHn 
can act as a shuttle protein transporting viral and cellular proteins between the cytoplasm 
and nucleus [60-62]. There is also evidence suggesting a possible role for nueleolin in 
cancer etiology. Cancer prognostic markers known as AgNORs (sitver-stained nucleolar 
organizer regions) have been shown to contain nueleolin in large amounts [63,64], and it 
has been shown there are increased levels of nueleoin in rapidly proliferating cells such 
as cancer cel1s [65]. 1t has also been previous1y observed in our group that nucleoHn is 
present on the surface of several malignant cell lines while absent on the surface of 
normal cell lines (unpublished observations). 
It is our hypothesis that active GROs exert growth inhibitory effects on malignant 
cells by binding and modulating specific proteins that affect relevant pathways. 
Nucleot1n is a known OttO binding proteIn that has previously been seen on the surface 
of cancer cells but primarily absent on the plasma membrane of nonmalignant cells. 
GROs could bind to nueleolin and inhibit the function of nucleolin, and/or GROs could 
be internalized by surface nucleo1tn and al10w OROs to bind and modify the t'unction of 
proteins other than nueleolin. The purpose of this project is therefore to elucidate the 
precise molecular mechanism of GRO antiproliferative activity against cancer cells 
by identifying the relevant proteins that interact with GROs and elucidating the 
21 
pathways affected by them. We propose that by investigating molecular changes in 
ORO binding proteins and incorporating global expression data, the at't'ected biological 
pathways can be identified. Knowledge of specific cellular proteins and pathways 
affected by GROs may lead to new molecular targets in the treatment of cancer, design of 
small m01ecule inhibitors, and better prediction of therapeutic response of cancer. The 
specific aims of this dissertation have been: 
Specific Aim 1: To identify GRO binding proteins and confirm binding by diverse 
methodology. 
Specific Aim 2: To investigate changes in levels, localization, and activity in GRO 
treated cells. 
Specific Aim 3: To confirm the relevant biochemical pathways involved in the 
mechanism or GAO andproliterative activity using proteomic and microarray 
analysis. 
Rationale 
GROs inhibit the proliferation of cancer cells in vitro and in vivo by a mechanism 
that is completely different from conventional chemotherapeutic drugs or traditional 
oligonucleotide strategies. One important GRO-binding protein has been identified as 
nuc1eotin, which has many cel1u1ar functions. ORUs could directly inhibit the tUnction 01' 
nucleolin, however, it is difficult to detennine which function because of the numerous 
22 
actions of nucleolin. If nucleolin is the primary target, we would anticipate that the 
identified GRO binding proteins may interact with nucleoiin and be involved in 
nucleolin-regulated processes such as such as ribosome biogenesis or apoptosis. 
Alternatively, nucleolin on the surface of the cell could bind to the GRO and transport the 
G-quartet inside the ceit. the GRO couid then bind to other intrace11ular targets and 
affect a number of cellular pathways. We would then expect the identified GRO binding 
proteins to be involved in functions unrelated to nucleolin. 
23 
CHAPTERll 
IDENTIFICATION AND ANALYSIS OF PltOTEJNS THAT IUN» TO 
GUANINE-RICH OLIGONUCLEOTIDES 
INTRODUCTION 
Cancer is a major public health problem and is estimated to cause more than half 
a million deaths annually in the United States [66]. Prevention, screening and treatment 
regimens have improved over the last decade; however toxicity from treatment still 
remains a problem. this has lead to considerable interest in the development of" novel 
tumor-specific agents such as oligonucleotide therapy. Oligonucleotide therapy is 
attractive due to the expectation that they will produce a response that is tumor-specific 
and theretore, effective without toxicity to normal cells [67]. the strategies utftized by 
oligonucleotide therapy include antigene (also known as triplex forming 
oligonucleotides), antisense, siRNA, and aptamer recognition [7, 10]. 
We have previously reported a novel class of phosphodiester guanine-rich 
oligonucleotides (GROs) that exhibit antiproliferative effects against several cancer cell 
lines [34-31]. Upon treatment with OR-Os, celis undergo inhibition of DNA reptication, 3 
phase cell cycle arrest, and cell death [35]. The antiproliferative GROs were also shown 
to form a G-quartet, a stable secondary structure consisting of four coplanar guanines 
joined by itoogsteen hydrogen bonding. Although aU active crItOs adopted the {I-quartet 
24 
motif, its secondary structure alone could not predict the antiproliferative activity of 
(Htt>. However, the biological activity of ORb could be determined by its ability to bind 
to a complex of proteins, one of which has been identified as nucleolin [34, 36]. 
Nucleolin is primarily thought of as a major nucleolar protein expressed by 
proliferating cel1s, where it is direct1y involved in the regulation of ribosome biogenesis 
and maturation [41]. There have been numerous reports, however, implicating nucleolin 
in several different biological functions such as cell growth and proliferation [40-42], 
ribosome biogenesis [40, 43], VNA repHcation [44], cytokinesis and nuc1ear division 
[45], and apoptosis [46,47]. Nucleolin can also function as a cell surface receptor, where 
it acts as a shuttling protein between cytoplasm and nucleus [60-62]. Nucleolin may also 
playa rote in cancer progression due to its critical involvement in ceil proliferation [42] 
and increased expression in rapidly proliferating cells such as cancer cells [65], which 
may be implicated in the mechanism of GROs. 
GROs may have significant therapeutic potential as anticancer agents with much 
less toxicity than conventional cytotoxic drugs. There are important aspects known about 
the function of GROs, such as ce11 cyc1e arrest and nuc1eotin binding. However, the 
precise molecular mechanism of GROs is not known; a powerful tool in deciphering the 
mechanism of GROs is the identification of GRO-associated proteins. Here we report 
that the binding of GROs to a complex of proteins posiviteiy correlates with the 
antiproliferative activity of GRo. To further elucidate the mechanism of GROs, the 
25 
proteins that bind to GROs in vitro have been analyzed and identified by mass 
spectrometry. 
MATERIALS AND METHODS 
Oligonucleotides 
All oligonucleotides have a phosphodiester backbone, were purchased in the desalted 
form from Integrated DNA Technologies Inc. and used without further purification. 
Oligonucleotides were resuspended in water, sterilized by filtration through a 0.2 /-lm 
filter, then diluted with sterile water to give stock solutions of 400-500 /-lM that were 
stored in aliquots at -20°C. Sequences of oligonucleotides used were as follows: 
GR029A, 5'-d(TTTGGTGGTGGTGGTTGTGGTGGTGGTGG)-3'; GR015B, 5'-d(TT-
GGGGGGGGTGGGT)-3'; AGROIOO, 5' -d(GGTGGTGGTGGTTGTGGTGGTGG-
TGG)-3'; GR015A, 5'-d(GTTGTTTGGGGTGGT)-3'; TEL, 5'-d(TTAGGGTTA-
(JuuTIAuuuttAuu)-3·". For the experiment shown in Figure 7, the fotlowing biotin 
(Bt) linked versions of GR029 and 15B were used: 5' -Bt-d(TTTGGTGGTGG-
TGGTTGTGGTGGTGGTGG)-3' and 5' -Bt-d(TTGGGGGGGGTGGGT)-3'. 
Electrophoretic Mobility Shift Assay (EMSA) 
TEL oligonucleotide was radiolabeled with 32p using T4 kinase. At the indicated 
concentrations, labeled oligonucleotide was preincubated alone or in the presence of of 
an unlabeled competitor oligonucleotide for 30 min at 37°C. HeLa nuclear extracts 
(bandshift grade: Promega, Inc.) were added, and samples were incubated for an 
additional 30 min at 37°C. Preincubation and binding reactions were carried out in buffer 
26 
A(20 mM Tris·HCL, pH 7.4, 140 mM KCI, 1 mM dithiothreitol, 0.2 mM 
phenylmethanesulfonyl fluoride, and 8% v/v glycerol). Electrophoresis was carried out 
using 5% polyacrylamide gels in TBE buffer (90mM Tris-borate and 2 mM EDTA). 
Identification of candidate GRO-binding proteins 
Extracts were prepared from HeLa cells as previously described [47]. Samples (250 flg) 
were incubated with a biotin-linked active GRO (GR029A) or biotin-linked inactive 
control oligonucleotide (GROI5B). The oligonucleotide-associated proteins were then 
captured by streptavidin precipitation (Streptavidin Magnashere Paramagnetic Particles, 
Promega) and electrophoresed on SDS-polyacrylamide (8%) gels. Silver staining was 
used to identify bands present in the GR029A-precipitated lane but absent in the control 
CJitOljB lane. these bands were excised, subjected to trypsin digestion, and ana1yzed by 
MALDI-TOF mass spectrometry analysis as described [19]. 
RESULTS 
Activity of GRO correlates with protein binding 
Because GROs have no anticipated antisense interactions, and they are capable of 
forming G-quartet structures, we hypothesized that the growth inhibitory effects of GROs 
results from the binding to (and subsequent moduiation ot) certain cel1ular proteins. 
Electrophoretic mobility shift assay (EMSA) analysis of radiolabeled GRO and nuclear 
extracts revealed a GRO-protein complex that correlates with the antiproliferative activity 
ot" ORO. Nuc1ear extracts were incubated with unlabeled active ORO (29A and 2613), 
inactive GRO (lSB), or a GRO with intermediate activity (15A) that competed with 32p_ 
27 
labeled TEL, which represents the human telomere sequence that is a G-quartet forming 
otigonuc1eotide. The absence of the indicated comp1ex correlates with the 
antiproliferative activity of each GRO (See Figure 7). 
Identification of GRO binding proteins 
To identify the proteins that bind to active GROs, precipitation with biotinylated 
oligonucleotides was used to isolate the proteins in nuclear and cytoplasmic extracts that 
bind to active GR029A and inactive GR015B. Running the samples on an 8% SDS 
polyacry1amide get revealed several proteins that bind to the active <Jtt029A but not to 
the inactive GR015B (see Figure 8). The bands visible in the GR029A sample but not 
present in the GR015B sample were excised and subjected to proteomic analysis using 
MALV1-'fOt<' mass spectrometry to identify the proteins that bind to <JROZ9A (See 'fable 
2). One of the GRO-binding proteins was identified as nucleolin, a previously identified 
GRO binding protein that is implicated in GRO antiproliferative activity [34], thus 
validating the technique. 'fhe additional 14 proteins identitied to associate with the active 
GRO are summarized below: 
Polypyrimidine tract-binding protein (PTB)-associated splicing factor (PSF) 
PSF is a 100 IDa polypeptide that was first identified and characterized in a 
complex with PTB. The polypyrimidine tract is a region found in most introns where 
several factors bind and is important for characterizing the 3' splice site. PSF binds to 
po1ypyrimidine tracts and is an essential tactor required during the second catalytic step 
in splicing [68]. Additional examples exhibiting the role ofPSF in pre-mRNA splicing 
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Figure 7: Activity of GROs correlate with protein binding. 
EMSA analysis of HeLa nuciear extracts and 32P-iabeled TEL (representing human 
telomere sequence) showing the complex formed by the nuclear proteins and TEL as 
indicated by the arrow. Unlabeled GROs compete for the complex that correlates with 
the activity of ORO. 
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Activity _____ ++ ++ + 
Cold compemor ---+- None 29A 156 268 15A 
Concentration of ::l<' P-TEL (nM) 
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Figure 8: Identification of GRO binding proteins. 
Nuclear and S-100c extracts (lOO·/-lg) from HeLa cells were incubated with biotinylated 
active ORO (29A) or biotinylated inactive ORO (15B). The bound proteins were then 
captured by streptavidin and run on an 8% SDS polyacrylamide gel. Silver staining 
revealed several bands present with the 2~A but absent with the contro1 1513 as Indicated 
by the arrows. These bands were excised and identified by MALDI-TOF mass 







Table 2: Nuclear and cytoplasmic proteins identified by mass spectrometry that 
precipitated with the active GRO. 
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Table 2: Specific GR029A binding proteins 
Nuclear binding proteins Cytoplasmic binding proteins 
nucleolin HSP 90(3 
PSF (3 Tubulin 
P54nrb actin 
HnRNPC 
Transcription factor iliA 
alpha synuclein 
complexin I 
immunoglobulin heavy chain 
HnRNPA1 
cytochrome oxidase VIC 
NFdr.e essential modulator 
HnRNP A21B1 
RAD50 repair protein 
ribosomal protein L 19 
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include: PSF is a component of the spliceosome C complex [69], PSF physically 
interacts with U lA in a comptex that tUnctions in splicing and po1yadenytation [70], and 
PSF has been shown to bind to RNA polymerase II [71]. It has also been shown that PSF 
is involved in binding and nuclear retention of defective RNAs [72] [reviewed in [73]]. 
PSF also demonstrates activity involved in DNA unwinding and DNA pairing. 
PSF co-purifies with topoisomerase I and partially co-localizes with topoisomerase I in 
interphase ceUs. In vitro studies have shown that the addition of recombinant PSt<' to 
purified topoisomerase I increases the specific activity of the enzyme (74]. PSF has also 
been shown to exhibit DNA reannealing activity by forming a DNA duplex from two 
homologous tJNA strands [75]. 
In regards to tumorigenesis, PSF may playa role in proliferation. Transformed 
ce11s show e1evated 1evels of PSt<' compared to non-immorta1fzed ce11s. Additiona11y, 
proliferating cells exhibit two-fold higher activity of PSF than quiescent cells, suggesting 
a possible role for PSF in proliferation [76]. 
P54nrb 
P54nrb was originally purified as a heterodimer with PSF [77], and it is highly 
hom01ogous to the C-terminus ofPSF [78]. 1n fact, many reports have indicated p54nrb 
and PSF copurify and share many functions within the cell. One of which is pre-mRNA 
processing. P54nrb forms a complex with PSF that interacts with UIA and functions in 
spiicing and polyadenylation [70]. Like PSt', p54nrb has been shown to bind to RNA 
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polymerase II [71]. P54nrb also shares with PSF the function of binding and nuclear 
retention of defective RNAs [72]. Another common function of pj4nrb and PSlf is VNA 
unwinding, p54nrb copurifies with PSF and topoisomerase I and exhibits functional 
activity on the enzyme [74]. 
Heterogeneous nuclear ribonucleoproteins (bnRNPs) At, A2lBt, and C 
HnRNPs were first described as a family of proteins bound to RNA polymerase II 
transcripts to form hnKNP partic1es [791, and there are now 19 hnRNt' members 
identified in the family [80]. All hnRNPs contain an RNA binding domain usually 
located at the N-terminus which is involved in sequence-specific binding of DNA or 
RNA. Another structurai motif found in hnitNPs is known as the Rtltl motif, which 
includes Arg-Gly-Gly tripeptide repeats. The RGG domain has been implicated in 
protein-protein interactions, RNA binding, transcriptional activation, and nuclear 
10catization [81]. 
The hnRNPs are involved in several cellular roles, one of which is DNA 
regulation. HnR:NtJ A2Ja 1 has been impticated in VNA repair as a negative reguiator by 
binding and inhibiting DNA-PK, a multi protein complex which controls DNA repair 
[82]. HnRNP C has also been identified as a protein that responds to double strand 
breaks of chromosomat DNA damaged by gamma irradiation [83]. ln addition, there is 
evidence supporting that hnRNP At and hnRNP A2lBt are involved in telomere 
biogenesis. In vitro experiments revealed that hnRNP At and hnRNP A2lBt bind to 
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human telomeric DNA sequences [84, 85]; furthennore, cells treated with siRNA to 
reduce expression ofim:R:NtJ Al and hnRNt' ALltH have shorter telomere taits [86]. 
HnRNPs have also been implicated in mRNA splicing. HnRNP AI, hnRNP 
ALlaI, and hnRNt' e have proposed functions in spiicing [81], with the most evidence 
supporting the role of hnRNP Al as a negative regulator in mRNA exon splicing. Site-
specific cross-linking and immunoprecipitation identified hnRNP Al as a protein bound 
to the c-Src exon. Moreover, addition of~ Al to an in vitro system decreased c-Src 
splicing [88]. 
Nuclear-cytoplasmic shuttling is another cellular function associated with 
hn:R.Nrs. HnRNP Al and hnRNt' e have been impticated in a proposed model ofnuc1ear 
export; hnRNP C contains a nuclear retention signal, while hnRNP Al contains a nuclear 
export signal. It is proposed that pre-mRNA is retained within the nucleus by hnRNP Al 
with hnRNP e also bound to the mRNA. Prior to nuc1ear export, hnRNP e dissociates 
resulting in the strand being exported out of the nucleus by hnRNP AI. Once in the 
cytoplasm, hnRNP Al dissociates from the mRNA strand and hnRNP Al is imported 
back into the nuc1eus [89]. 
HnRNPs have also been implicated in tumor development and progression. 
~xpressions ofhnRNP Al and hnRNP AL/tn have been shown to vary at ditferent stages 
of the cell cycle, peaking at S phase in squamous carcinoma cells; but more importantly, 
cell proliferation decreased upon treatment with siRNA decreasing expression of hnRNP 
37 
Al and hnRNP A2IBI [90]. Additionally, expression levels of many hnRNPs are altered 
in different cancer tissues. Lung cancer tissue has increased levels of hn:ltNt' AI, hnltNP 
A2IBI, and hnRNP C [80]~ there is also evidence suggesting hnRNP A2IBI could be 
useful in detection of preclinical lung cancer [91]. Increased levels ofhnRNP A2IBI are 
a1so seen in cancer tissues of the breast, pancreas, stomach and esophagus [SO]. 
Transcription factor IlIA (TFIIIA) 
TFIIIA is a zinc metalloprotein that contains nine consecutive zinc finger domains 
that function in sequence-specific binding of DNA and RNA [92]. TFIIIA has two 
functions in eukaryotic cells, the first being a transcription factor that regulates the 
expression of the j S ribosoma1 RNA gene. TMltA first binds to the internal contr01 
region (ICR) on the gene, which subsequently initiates an ordered assembly of factors 
that form a functional transcription complex [93]. TFIlIA also functions as a 5 S RNA 
transcript chaperone that moves the transcript from the nuc1eus to the cytoplasm [94]. 
a-synucleJin 
a-synuclein is a 140 amino acid neuronal protein that has been implicated in 
several neurodegenerative diseases. It was first discovered by a point mututaion linking 
the protein to a rare familial form of Parkinson's disease (PD) [95]. Subsequently, other 
mutations in the a-synuclein gene have been identified in familial PD [96, 97]. Cellular 
inclusions called Lewy bodies are found in several neurodegenerative diseases such as 
PD and cortical Lewy body dementia. It has been shown that a-synuclein is the primary 
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protein component of Lewy bodies, and a-synuclein has been implicated in the etiology 
ofthese diseases [reviewed in [98]]. 
Complexin I 
Complexins constitute a small family of neuronal proteins that include two 
closely related isoforms known as complexin I and complexin II. The complexins playa 
critical role in regulating the Ca2+-dependent neurotransmitter release [99]. In gene 
knockout studies in mice, down regulation of complexin I resulted in reduced transmitter 
release caused by decreased sensitivity to Ca2+ in synaptic secretion process [100]. 
Additionally, it has been observed that complexin I mRNA levels are decreased in the 
hippocampal subfields of patients with schizophrenia or biopolar disorder [10 Ij. 
Immunoglobulin heavy chain variable region 
The basic subunit of an antibody molecule is a pair of identical Ig heavy chains 
(IgH) and a pair of identical Ig light chains (IgL). The N-terminal portion of the heavy 
chain and light chain has a variable and unique amino acid sequence that is known as the 
variable region~ this variable region is involved in specific antigen binding. Variable 
regions of antigen receptors, like IgH, are assembled by a process known as VDJ 
recombination (variable, diversity, and joining gene segment recombination) [reviewed in 
[l01]]. Analysis of the VVJ recombination on 19H genes has been shown to be a useful 
marker in diagnosing the pathology of several lymphomas [reviewed in [103]]. 
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Cytochrome c oxidase subunit VIc 
Cytochrome c oxidase is a complex protein that transfers electrons from 
cytochrome c to oxygen in the last step of the mitochondrial respiratory chain. There are 
13 individual protein subunits composing cytochrome c oxidase: I, II, III, IV, Va, VIa, 
Vtb, Vtc, 'Ytta, Vitb, VUc, and viit. Subunits t, it, and iii are encoded by mitochondrial 
DNA, and comprise the catalytic core. The remaining subunits are synthesized from 
cellular nuclear DNA [reviewed in [104]]. Although more work is needed to elucidate 
the precise rote of subunit Vic, there is evidence suggesting its presence is crucial for the 
activity of the enzyme. Null mutants for subunit VIc show a complete loss of cellular 
respiration [105, 106]~ subunit VIc is considered essential for stability of the complex 
fl 07] and criticat is the ordered sequence of assembly events [lOS]. 
NF-ldJ essential modulator (NEMO) 
NF-KB refers to a family of transcription factors that regulates the expression 
genes controlling the immune and stress response, inflammatory reaction, cell adhesion, 
and apoptosis [reviewed in [109]]. The classical activation of NF-KB is a tightly 
controlled process where the active NF-lCB complex is a homo- or heterodimer composed 
of proteins from the NF-KBlRel family. In its inactive state, NF-KB resides in the 
cytoplasm bound to a complex with its inhibitor protein, IKB. When an extracellular 
signal, such TNF-a. or IL-I, binds to the appropriate cell surface receptor, the signal is 
transferred by adaptor proteins. The IKK complex (consisting of IKKa., IKKf3, and 
NEMOlIKKy) then becomes activated and is able to phosphorylate IKB, which then 
disassociates from the NF-KB dimer. The unbound NF-KB dimer is then free to move 
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into the nucleus and drive transcription of many genes [110]. NF-KB signaling is 
frequently deregulated in cancer encoding a variety of genes expressing pro-proliferation 
and anti-apoptotic proteins, and the down-regulation ofNF-KB has become an attractive 
strategy for developing new cancer treatments [Ill]. 
RAD50 repair protein 
Rad50 is a key protein component of the MRElllRAD50INBSl (MRN) complex 
which is a central player in ce11u1ar response to DNA double-strand breaks. The MKN 
complex is involved in a variety of processes such a homologous recombination, non-
homologous end joining, telomere maintenance, and DNA damage checkpoint activation. 
AAtJj() and M1tt!11 form the core of the MltN complex, with t{At)j() functioning in 
DNA binding activity. The MRN complex has three primary functions, the first being 
DNA damage recognition. The MRN complex binds to the damaged DNA and activates 
the AiM kinase protein. 'the second is tUnction is ATI?-driven nuc1ease activity. The 
MRN complex creates a clean DNA end that can be further processed in homologous 
recombination or replication fork rescue. The third function is involves linking DNA 
ends with other sister chromatids; this function is important in cell processes such as 
meiotic recombination or T-Ioop and D-Ioop formation in telomeres [complete review in 
[112]]. 
Ribosomal protein L19 
Ribosomes are complex macromolecules that consist of rRNA and ribosomal 
proteins, with rttNA comprising the catalytic center and ribosomal proteins at the 
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periphery of the structure. Biochemical and structural evidence shows that ribosomal 
proteins are involved in every translation process with the exception of peptide 
transferase at the catalytic center. Specifically, ribosomal proteins playa role in the exit 
of the polypeptide from the ribosome. The tunnel exit is a very important location in 
which the nascent chain can interact with externa1 t~tors; the exit area is encirc1ed by 
several ribosomal proteins, including ribosomal protein L19 [113, 114]. Additionally, 
increased levels of ribosomal protein L 19 have been shown in human breast tumors that 
overexpress the erb13-1 gene [II;]. 
Heat shock protein 90Ji (HSP90Ji) 
HSP90 is an abundant molecular chaperone that assists in the correct folding and 
maturation of cellular proteins. There are two isoforms with 85% identity, HSP90a and 
HSP90rl, which exhibit no significant difference in properties. HSP90 exists as a 
homodimer bound by the C-terminal domain; the N-terminal domain contains the binding 
site for A TP. The chaperone activity of HSP90 depends on the conformational cycling 
between opening and closing a molecular clamp, which is dependent upon ATPase 
activity [1l6]. ttSrt)t) is impticated in a variety of post-translational functions, such as 
translocation of proteins across membranes, assembly/disassembly of transcriptional 
complexes, and regulation of signaling molecules [117]. Because of its 
mu1tifunctionatity, ttSpt)t) has several substrates inc1uding the lKK complex [118], SV4t) 
large T-antigen [119], and actin [120]. 
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There has been intense interest in inhibitors of HSP90 as anticancer therapy. 
There is increased expression of HSt'90 in severa1 human cancers; specificaHy, 
overexpression of HSP90 in breast cancer correlates with poor prognosis [121]. Both 
cytotoxic and cytostatic anticancer activities have been reported for HSP90 inhibitors in 
ce11 culture models and animal tumor models, and inhibitors of HSt'90 are now entering 
clinical trials with great expectations [reviewed in [117]]. 
f3-tubulin 
Microtubules are the dynamic pipe-like proteins which are the primary component 
of the cytoskeleton. They are primarily composed of (X- and j3-tubulin heterodimers that 
aggregate in a head to tail arrangement to form long tubes that constitute proto filaments, 
and prototllaments form the pipe-Hke microtubule structure. Microtubuies are inv01ved 
several processes, one of which is to form the mitotic spindles required for the movement 
of chromosomes to the poles of the new cell during cell division. Another function of 
microtubuies is to give ce11s both shape and organized structure. Microtubuies also 
provide the tracts for transport of vesicles, organelles, and mitochondria. These critical 
cellular functions make microtubules a target for anticancer drugs. There are already 
severa1 successful anticancer drugs that target tubuiin inc1uding taxanes, colchicines, and 
vinca alkaloids [complete review in [122]]. 
Actin 
Actin is a major protein in eukaryotic cells and an essential component of the 
cytoskeleton. Actin filaments provide the basic infrastructure in functions such as 
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maintaining cell morphology, adhesion, motility, exocytosis, endocytosis, and cell 
division [123]. 1t has become evident that actin filaments are reguiated by signai 
transduction pathways of the GTPase Ras superfamily (Rac, Rho, and Cdc42) [124]. 
There is accumulating evidence that actin remodeling is involved in the growth and 
motitity of matignant ceUs. 13ecause of this, there is an interest in targeting actin 
polymerization as an anticancer agent with focus on actin binding proteins and the 
GTPase Ras signaling pathway [reviewed in [125]]. 
DISCUSSION 
We have previously described the potent antiproliferative effects of G-rich 
otigonuc1eotides in severat matignant ce1t tines [34-371 with a novel mechanism 
unrelated to antisense or antigene activity. Although the precise molecular mechanism is 
unknown, we have demonstrated that the growth inhibitory effects of these 
oiigonucteotides correlate with their abitity to bind to a specific ceiiular protein complex, 
as seen in Figure 7 [34, 36]. Because of this significant relationship between 
antiproliferative function and protein binding, we investigated the proteins that bind to 
OROs to give insight into the precise mechanism of OR-OS. Several proteins were 
identified by mass spectrometry to bind to a functionally active GRO as seen in Table 2~ 
however, these GRO-protein associations should be confirmed by other methods such as 
Western biot analysis to ensure to the authenticity of the interaction. 
One important protein identified as a GRO-binding protein is nucleolin, and 
nuc1eotin has been previously identified as the primary target in the antiprotitbratve 
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activity of GROs [34]. Therefore, there are two possible scenarios that exist either 
OROs bind to the specific proteins or protein complexes directiy, or OROs primari1y bind 
to nucleolin which precipitates the additional proteins identified. The latter seems more 
plausible due to extreme multifunctional nature of nucleolin. Review of the functions of 
the identified ORb-binding proteins revealed severa! celiular processes in which 
nuc1eolin has been implicated such as rRNA maturation, ribosome assembly, DNA 
repair, telomere maintenance, mRNA binding, and nUcleocytoplasmic transport [41]. 
Additionaiiy, several of the ORO-binding proteins identified have previously been shown 
to associate with nucleolin: hnRNP Al [126], hnRNP C [127], HSP90 [126], and actin 
[51]. 
It is our hypothesis that active GROs exert growth inhibitory effects on malignant 
cells by binding and modulating specific proteins that affect relevant pathways. 
Although more work is needed to e1ucidate the precise m01ecu1ar mechanism, the 
identification of GRO-binding proteins gives insight into some of the possible cellular 
processes affected by GROs. 
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CHAPTERID 
AGROIOO INHIBITS ACTIVATION OF NUCLEAR FACTOR-1C.B (NF-1C.B) BY 
FORMING A COMPLEX WITH NEMO AND NUCLEOLIN 
INTRODUCTION 
Many common types of cancer, especially in their advanced stages, do not 
respond well to traditional chemotherapic agents or may acquire resistance to therapy. 
Novel agents that work by mechanisms that are different from existing therapies, 
particularly those that are able to target multiple pathways important for cancer ceil 
survival, may therefore be useful in the treatment of advanced cancer. We have reported 
previously that certain guanosine-rich phosphodiester oligodeoxynucleotides, termed 
<J:ROs, have antiprotiferative activity against a variety of cancer ceil tines [34-37]. 
Furthermore, an active GRO (named GR029A) can cause cell cycle arrest and induction 
of cell death in human cancer cell lines, but not in non-malignant human cells [35]. 
troitowing pre-ctinicat in vivo studies that demonstrated that it had no detectable toxicity 
in normal tissues [38], a truncated version of GR029A known as AGROlOO (recently 
renamed AS1411), has been tested in a Phase I clinical trial of patients with advanced 
cancer. The results of this tria1 were recently presented [38j and indicated that AG:ROlOO 
was well tolerated (no toxicity was observed) and had promising clinical activity. 
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In previous in vitro studies, we have examined a series of G-rich sequences in 
order to determine a structure-activity relationship and to gain insight into their novel 
mechanism [34, 36,37]. We found that active GROs can have diverse G-rich sequences, 
but all could adopt folded conformations that are stabilized as G-quartets. However, 
tbrmation of a stable tl-quadrup1ex was not suftlc1ent for activity. tn addition, there was a 
very good correlation between the biological activity of GROs and their abilities to form 
a specific complex containing a protein that was identified as nucleolin [34, 36, 37]. 
There is strong evidence from UV crosstin1dng and southwestern blotting [341 that tlROs 
bind directly to nucleolin rather than interact through an intermediary protein, and 
therefore we have proposed that nucleolin is the primary target of GROs such as 
AGROlOtl. 
Despite their probable target having been identified, the detailed mechanism of 
action for tiRes is not yet fully understood. in part, this is because little is known about 
the role of nucleolin in cancer biology. Nucleolin protein is expressed at high levels in 
rapidly proliferating cells such as cancer cells [65], and nucleolin is a major component 
of a set of cancer prognostic markers (AgNrnts) whose levels are elevated in cancer celts 
compared to normal or pre-malignant cells [63, 64]. Although it is best known as a 
nucleolar protein with a role in ribosome biogenesis, nucleolin is in fact a remarkably 
muitifunctionat protein that can also be present in the nudeoplasm, cytop1asm and on the 
cell surface [40-42, 50-52]. In addition to its multiple functions in ribosome biogenesis 
[40-42], nucleolin is thought to playa role in numerous cellular processes, including 
apoptosis [41], signal transduction [41, 4S, ~r~, 91, 128], tlNA replication [44, ~4], 
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mRNA stability [127, 129, 130], protein trafficking [50, 131], stress response [132], and 
te10merase function [133j.lt has been reported by several research groups that nuc1eoHn 
binds to G-quadruplex-forming DNA sequences, such as the human telomere [85, 134], 
immunoglobulin switch regions [25] and ribosomal DNA [28], but the significance of 
these interactions in vivo has not yet been determined. 
Recently, we identified NEMO (NF1d3 essential modulator, also known as IKKy 
and IKKAPI) as a potential GRO-associated protein following mass spectrometry 
analysis of proteins that were precipitated when an active biotin-linked GRO was 
incubated with cancer cell extracts (see Chapter ll). It was selected for further 
investigation because of its important role in NF-1d3 signaling, a pathway which is often 
deregulated in cancer cells [110, 135, 136], and which has been reported previously to be 
inhibited by polyguanosine sequences [137] via an uncharacterized mechanism. "NF-KB" 
refers to a family of proteins that function as dimeric transcription factors to affect the 
expression of genes involved in immune and inflammatory responses, cell growth, 
differentiation and apoptosis [136, 138, 139]. In non-stimulated cells, NFKB is normally 
bound to an inhibitor called 11d3u, which sequesters it in the cytoplasm in an inactive 
state. Upon ligation of an appropriate cell surface receptor (for example, by TNFu), the 
IKB kinase (IKK) complex consisting of NEMO, IKKu, and IKKf3 becomes activated. 
This IKK complex then phosphorylates 11d3u, leading to its ubiquitination and flagging it 
for degradation by the 26S proteasome. Upon degradation of I1d3u, NF-KB is released 
and translocates to the nucleus to activate gene expression. Targets of NF-1d3 include 
many anti-apoptotic and pro-proliferation genes and this pathway is constitutively 
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activated in many human cancers [110, 135, 136]. For this reason, NF-K8 and the 
proteins that control its activation have become interesting targets for cancer drug 
discovery [136, 139]. 
The purpose of the present study was to further investigate the significance of our 
preiiminary observation that NEMO associates with an active (J-rich otigonuc1eotide. 1n 
particular, our aims were to verifY that AGR0100 was associated with NEMO in treated 
cancer cells, to determine the biological consequences of this association and to 
investigate the possibie roie of nuc1eoHn in mediating it. 
MATERIALS AND METHODS 
Oligonucleotides 
The oligodeoxynucleotides used in the present study were AGR0100, an antiproliferative 
GRO whose sequence is Y-d(GGTGGTGGTGGTTGTGGTGGTGGTGG)-3', and 
CR016, an inactive contro1 oHgonuc1eotfde whose sequence is ,. -
d(CCTCCTCCTCCTTCTCCTCCTCCTCC)-3'. All oligonucleotides had a 
phosphodiester backbone and, unless otherwise stated, were purchased in the desalted 
tbrm from Integrated t>NA 'technotogies Inc. (Cora1vi11e, IA) and used without further 
purification. Oligonucleotides were resuspended in water, sterilized by filtration through 
a 0.2 J..Ul1 filter, then diluted with sterile water to give stock solutions of 400-500 J.1M that 
were stored in aliquots at -20°C. For experiments shown in Figure 10, the following 
biotin (Bt) linked versions of AGR0100 and CR026 were used: 5'-Bt-
d(TTTGGTGGTGGTGGTTGTGGTGGTGGTGG)-3', purchased from MWG Biotech, 
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and 5'-Bt-d(TTTCCTCCTCCTCCTTCTCCTCCTCCTCC)-X-3', where X is a 
propyiamine modification, synthesized on a Beckman 1 ()()OM instrument as previously 
described [35]. 
Cell culture and treatment 
Ceil lines used were HeLa (human cervical cancer), DU145 (human prostate cancer), 
A549 (human non-small cell lung cancer), MCF-7 (human breast cancer) and Hs27 (non-
malignant human skin fibroblasts), which were obtained from American Type Culture 
Co11ection (A iCC, Manassas, V A). Cet1s were grown in a standard incubator in DMEM 
(Gibco) supplemented with 10% heat-inactivated (65°C for 20 min) fetal bovine serum 
(Gibco) or charcoal-stripped fetal bovine serum (Biomeda, for MCF-7 only), 100 
units/ml penici11in and 1 ()() units/mt streptomycin. For the ceit protiferation assays 
(Figure 9), cells were plate at low density (1000 cells per well or 2000 cells per well for 
MCF7 and Hs27) in 96-well plates and incubated 18 h at 37°C to allow adherence. They 
were treated by addition of AGR0100 directly to the culture medium to give the final 
concentration indicated in the figure. Cells were incubated for a further 5 days in the 
presence of oligonucleotide and then proliferation was determined using the MTT assay, 
as previously described [341. Por aU other experiments, unless otherwise stated, ce11s 
were plated in 6-well plates at about 50% confluence and incubated 18 h to allow 
adherence, then treated by addition of oligonucleotide directly to the culture medium. 
Where indicated, TNFa (R & D Systems, Inc.) was added to the culture medium to a 
final concentration of7.5 nglml. 
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Capture of biotinylated GRO-protein complexes from BeLa cells 
Cells were grown in 6-well plates as described and treated by addition of biotin-
hnked oiigonucleotide at 3 ~M final concentration. After incubation for 2 h at 37!)C, cells 
were lysed under mild conditions and proteins associated with biotinylated 
oligonucleotides were captured by streptavidin precipitation, as described previously 
[34]. Captured proteins were electrophoresed on SDS-polyacrylamide (8%) gels and 
transferred to PVDF membranes. Membranes were blocked with 5% nonfat dried milk in 
PBS plus 0.05% Twe.e.n20 (PBST) the.n incubate.d with prllnary antibody in PBST (1 
~glml anti-nucleolin, sc-8031, Santa Cruz or 1 ~glml anti-NEMO, sc-8032, Santa Cruz). 
Following incubation with secondary antibody (0.5 ~glml anti-mouse HRP-conjugated, 
Santa Cruz) bands were visualized by chemiluminescence (ECL, Amersham 
Biosciences ). 
IKK kinase assay 
HeLa cells were plated in 6-well plates as described. After 1 h incubation with 
oligonucleotide, TNra was added for a further 30 min. Celllysates were prepared using 
0.1 M Tris.HCI pH 8.0, 1% Triton X-IOO, 1% deoxycholate, 0.5% SDS, 2 mM 
phenylmethylsulfonyl flouride (PMSF). The lysates (1 0 ~g) were then assessed for IKK 
kinase activity as previously described [140], utilizing 2.5 J,lg of IKBa-GST fusion 
protein (Santa Cruz) as the substrate. The gels were dried and analyzed by 
autoradiography. 
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Detection of phosphorylated Ida 
HeLa cells were treated exactly as described for the IKK kinase assay. Lysates were 
prepared by addition of lysis buffer (62.5 mM Tris.Hei pH 6.8,2% SDS, IODIO glycerol, 
50 mM dithiothreitol), electrophoresed on 8% polyacrylamide-SDS gels and transferred 
to PVDF membrane. Western blot analysis was then performed using anti-phospho-IKBa 
antibody (1 !lglml, Cell Signaling Technology). To visualize the total protein loaded, the 
membrane was stained with 3 drops of Higgins India Ink 4415 in PBSlTween 20 for 2 
h.ours and washed \\'ith PBSlTween 20. 
Transient transfection and measurement of luciferase activity 
Cells were plated in 24-well plates at a density of 2 x 104 cells per well and were 
transiently transfected with an NF-KB reporter plasmid and an internal control plasmid 
(described below) usin~ Superfect rea~ent (Qia~en), accordin¥ to the manufacturer's 
protocol. At 24 h post-transfection, oligonucleotide was added directly to the medium for 
the final concentration indicated. After Ih incubation, recombinant TNFa was added to 
the medium for 6 h (where indicated) and celllysates were prepared using reporter lysis 
buffer (Promega). Lysates were added to the substrate reagents supplied in the Dual-
Luciferase reporter system (Promega) and luciferase activity was measured using a 
luminometer (Zylux corporation). The NF-KB reporter plasmid contained tandem repeats 
of the KB sequence upstream of the minimal simian virus 40 (SV40) promoter and firefly 
luciferase gene in pLuc~Me5 vector (5tratagene) and was a kind gift: from Dr. Fajan 
Yang. As an internal control to account for variations in transfection efficiency, pRLnull 
(Promega), which expresses Renilla luciferase by basal transcription, was used (a gift 
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from Dr. Robert Mitchell). Luciferase activity is expressed as the activity of firefly 
1uciferase divided by Renilia 1uciferase. 
Immunoprecipitation of nucleolin 
HeLa ceils were plaied as described. After 1 h incubation with oligonucleotide, TNFa 
was added for a further 2 h and then S-100 extracts were then prepared [47]. The extracts 
(100 JIg) were incubated with 10 /J.g of anti-nucleolin antibody (sc-8031, Santa Cruz) for 
2 h at 4°C in RIPA buffer (150 mM NaCl, 10 mM Tris.Hcl pH 7.5,0.1% SDS, 1% Triton 
X-100, 1% Deoxycholate, 5 mM EDTA, 1mM PMSF, 2 /J.g/ml leupeptin). Goat anti-
mouse coated magnetic beads (Magnabind, Pierce) were then added to the samples and 
incubated for 1 h at 4°C. The beads were captured and unbound sample was removed by 
washing three times with RIP A buffer. The precipitated proteins were eluted from the 
beads by the addition of SDS sample loading buffer (4% SDS, 2% glycerol, 5% fl-
mercaptoethanol, 0.75 M Tris.HCI, pH 8.8) and heating at 65°C for 15 min. Western blot 
analysis, as described above, was then utilized to detect the presence of NEMO and 
nucleolin. 
RESULTS 
Antiproliferative activity of AGROIOO 
In previous work [34], we have shown that a G-rich oiigonucleotide named 
GR029 A can inhibit proliferation in prostate, breast and cervical cancer cells. 
Subsequently, we determined that the 3' -amino modification and the three 5'- thymidines 
of tlKt>29A are not necessary for nuc1ease resistance or biotogical activity [3~, 371-
Therefore, AGROI00, the oligonucleotide selected for clinical development, lacks these 
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features and is an unmodified 26-mer oligodeoxynucleotide. Thermal denaturation 
experiments, carried out as previously described [341, indicate that Atlt{OlOO forms a 
stable structure that melts at 76°C (Bates, unpublished observations). As shown 
schematically in Figure 9, this structure is predicted [37] to be a bimolecular quadruplex 
that is stabilized by the formation of eight tl-quartets. 10 first verifY the antiproHferative 
activity in the cell lines of interest, AGROlOO was added directly to the culture medium 
and cells were incubated in the presence of the oligonucleotide for 5 days. This was 
fo11owed by determination of relative ce11 number using a colorimetric Mil assay. As 
expected, based on our previous studies of GR029A [34-37], micromolar concentrations 
of AGROIOO strongly inhibited the proliferation of a variety of human cancer cells, but 
had a lesser effect on Hs27 ce1is, which are non-matignant human skin fibroblasts (ttigure 
9C). 
NEMO is an AGROIOO-associated protein 
In preliminary experiments designed to identifY candidate proteins that may play 
a role in GRO activity, we incubated biotin-linked G-rich oligonucleotides with 
concentrated HeLa cell extracts in vitro. This was followed by streptavidin precipitation, 
electrophoresis of captured proteins and mass spectrometry analysis of bands that were 
precipitated by an active GRO but not a control oligonucleotide. Several specific GRO-
associated proteins were identified by this approach, including nucleolin and NEMO (see 
Chapter 11). 
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Figure 9: Structure and activity of AGROIOO. 
(A) Schematic diagram of the structure proposed [37] for AGROI00, which comprises 
two strands of AGROIOO folded in antiparallel orientation to form a bimolecular 
quadruplex containing eight G-quartets; (B) G-quartet showing the hydrogen bonding 
arrangement of the four planar guanosines; (t) Antiprotiferative activity of AOltOIOO in 
various human cell lines. Cells were incubated for 5 days following a single treatment 
with the indicated concentration of AGROIOO (which was added directly to the medium) 
and protiferation was measured using an MTr assay. The identity of the ceit Hne used 
and its origin are indicated in each graph. The ordinate indicates absorbance at 570 nm, 
which is directly proportional to the number of viable cells in the sample. Data points 
represent the mean of tripiicate samp1es with standard error bars. 
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To confirm that complex formation between NEMO and AGROlOO occurs in 
treated cancer ceUs, we incubated HeLa cervica1 carcinoma ceUs with biotin-Hoked 
oligonucleotides, then lysed the cells under mild conditions and precipitated with 
streptavidin. Western blot analysis of the streptavidin-precipitated proteins (Figure lO) 
revealed thatNt!Mt> was precipitated nom ce11s treated with biotin-tinked AtlItt> 1 00 but 
not from untreated cells or those treated with a biotin-linked C-rich oligonucleotide as a 
control. As expected, nucleolin was also specifically precipitated by biotin-linked 
AtJItt>lOO (figure 10). These experiments have been carried out at teast three times, with 
reproducible results. 
Inhibition of IKK activity in AGROIOO-treated cells 
Because NEMO is known to be essential for function of the IKK complex in the 
classical pathway ofNF-KB signaling [138], we next investigated the effect of AGROlOO 
treatment on IKK activity. First, we performed an IKK kinase assay, which assesses the 
capability of cell Iysates to phosphorylate the IKK substrate, IKBa, in the presence of 
radiolabeled ATP. HeLa cells were treated for I h with AGROlOO or CR026 and then 
stimulated with TNFa for 30 min. As seen in Figure IIA, there was substantial induction 
of IKK activity upon stimulation with TNF a in the absence of oligonucleotide. 
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Figure 10: NEMO and nucleolin are associated with AGR0100. 
HeLa cells were treated with biotin-linked AGR0100 (AGRO) or biotin-linked control 
oligonucleotide (eRO) or were untreated (-). After 2 h, cells were lysed under mild 
conditions and added to streptavidin-coated magnetic beads for precipitation of 
oHgonucieotide-associated proteins. The precipitated proteins were then subjected to 
western blot analysis to detect the presence of either nucleolin or NEMO. Non-
precipitated lysate (5 J.lg) was used for comparison, left lane. 
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Figure 11: AGROl00 iDhibits activity of the IKK complex. 
Lysates were prepared as described from HeLa cells that were treated for 1 h with 
AGROlOO (AGRO) or CR026 (CRO), at the concentrations shown, then stimulated with 
TNFa. for 30 min. (A) Lysates were used in an IKK kinase assay in the presence ofy}2p-
ATP and GST-IKBa as a substrate. The upper panel is an autoradiograph showing IKK 
kinase activity, as represented by phosphorylation of precipitated GST -IKBa.. The lower 
panel represents quantified IKK kinase activity determined by densitometry usin~ 
ImageQuant 5.2 software (Amersham Biosciences) with values shown relative to 
background activity; (B) Lysates were subjected to western blot analysis using an 
antibody specific for the phosphorylated form of IkBa. in order to detect IKK-mediated 
phosphorylation of the endogenous substrate. The lower panel represents densitometric 
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1 0 ~ concentration (J.1M) 
CRO ~ oligonucleotide 
Incubation of cells with AGROIOO abrogated the activation of the IKK complex in a 
dose-dependent manner, whereas treatment with the contr01 eft(:) had tittle effect. to 
validate these findings, we next used an additional method to examine the IKK -mediated 
phosphorylation of IlCBa. Western blot analysis using an antibody specific for the 
phosphorylated form of IKBa was performed using lysates from cells that had been 
treated for 1 h with AGROIOO or CR026 and then stimulated with TNFa. The 
membrane was subsequently stain~d (India Ink) to ensure equal amounts of protein were 
loaded and transferred. The results (Figure lIB) indicated that phosphorylation of IKBa 
occurred upon stimulation with TNFa, but was blocked by AGROlOO, whereas CRO had 
no effect. These observations correlated weli with the results from the IKK kinase assay. 
Inhibition ofNF-KB activation in AGROl00-treated cells 
Based on the previous result that IKK activity is inhibited, NF-lCB signaling 
would be expected to be blocked in cancer cells treated with AGROIOO. To confinn this 
prediction, we examined the activity of NF-td3 in cells that were transiently transfected 
with a NF-KB-driven luciferase reporter construct. Cells were first transfected for 24 h 
with the reporter construct (expressing firefly luciferase) plus an internal control vector 
(expressing Renilla luciterase) and then were treated with AGKOIOO or CR026 for 30 
min. TNFa was then added to the medium and cells were incubated for a further 6 h 
followed by measurement of luciferase activity. As shown in Figure 12A, treatment of 
HeLa cells with AGROIOO reduced TNFa-induced NF-KB transcriptional activity in a 
dose-dependent manner, but treatment with the CR026 control had no effect on NF-KB-
driven luciferase activity. Next, we used the reporter gene assay to determine the effects 
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Figure 12: AGR0100 inhibits NF-KB transcriptional activity. 
(A) HeLa cells were transiently transfected with a NF-lCB reporter construct expressing 
firefly luciferase and a control plasmid expressing Renilla luciferase. After 24 h, cells 
. 
were treated for 1 h with AGR0100 (AGRO) or control oligonucleotide. eR026 (eRO) 
at the concentration indicated, then stimulated for an additional 6 h with TNFa. and 
luciferase activity was then measured. The luciferase activity shown was calculated as 
firefly luciferase activity divided by Renilla luciferase activity and shown relative to the 
unstimu1ated activity. the bars represent the mean and standard error of triplicate 
experiments; (B) Similar experiments were carried out in the cell lines indicated at the 
top of each graph using 10 ~M AGR0100 or CR026; (e) The same assays were carried 
out in the absence of TNFa. simulation to determine the effect of AGR0100 on 
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of AGROIOO treatment on other types of cancer cells. Figure 12B shows that AGROIOO 
was able to inhibit TNFa-induced NF-KB activation in cell lines derived from human 
prostate cancer (DU145), breast cancer (MCF-7) and non-small cell lung cancer (A549). 
The effect on Hs27 cells was not determined because transfection efficiency in these cells 
was poor. tturiliermore, as demonstrated by simitar experiments carried out in the absence 
of TNFa, AGROlOO could also inhibit constitutive NF-K8 signaling in those cell lines 
that had significant basal NF-KB activity (Figure 12C). In either the absence or presence 
of TNFa, there was no significant effect of AGROIOO on the activity due to the control 
Renilla luciferase plasmid or on cell number, therefore excluding the possibility of non-
specific effects of AGROlOO on transcription, translation or cell viability (data not 
shown). 
Co-precipitation of NEMO and nucleolin from AGROIOO-treated cells 
Because both nucleolin and NEMO were precipitated with AGR0100, we 
proceeded to investigate the possibility that these proteins were simultaneously present in 
the same AGROIOO-containing complex within the cell. Immunoprecipitation with 
nuc1eoiin antibody was performed using extracts from HeLa cet1s that had been treated 
with AGROlOO or CR026 and then stimulated with TNFa. The immunoprecipitates 
were then subjected to western blot analysis to determine if NEMO was co-precipitated 
with nuc1eotin. ttigure BA demonstrates that in untreated ce11s, or ce11s treated with the 
controi oiigonucleotide, a very smali amount of NbMO was detected in the nuc1eoiin 
immunoprecipitate. However, when the cells were treated with AGROlOO and then 
stimulated with TNFa, significantly more NEMO co-precipitated with nucleolin, 
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indicating that NEMO, nucleolin and AGROlOO are present in the same complex. 
Although we cannot definitively exc1ude that A01{C>}()() is bound independentty to both 
proteins, a more likely explanation fur this result is that AGRO 100 binds directly to 
nucleolin and stabilizes a protein-protein interaction between nucleolin and NEMO. This 
idea is supported by the weak interaction between nuc1eotin and mMC> in untreated 
cells, which was confirmed in additional experiments (Figure 13B). 
DISCUSSION 
It has become clear in recent years that NF-KB signaling is frequently deregulated 
in many types of cancer [1lO, 135, 136]. NF-KB target genes encode a variety of pro-
proliferation and anti-apoptotic proteins, and it seems likely that malignant cells have 
acquired constitutive activation of this pathway in order to bypass the normal 
physiological signals that prevent uncontrolled proliferation or to resist apoptosis induced 
by radiation, chemotherapy or hormonal agents [llO, 135, 136]. Constitutive NF-KB 
activation may have particular significance with respect to advanced cancers and their 
resistance to therapeutic manipulation. For example, constitutive activity of NF-KB was 
not detected in hormone-responsive prostate cancer cell lines, but was detected in 
hormone-insensitive prostate cancer tines and in tumor tissue from patients with 
advanced prostate cancer, a disease that is very often resistant to therapeutic intervention 
[118, 141, 142]. Inhibition of NF-KB activation has also been linked to the 
chemopreventive properties of several compounds with activity in cancer, such as 
selenium, green tea, and silymarin [140, 143, 144]. Down-regulation ofNF-KB activity is 
therefore considered a very attractive strategy for developing new cancer treatments 
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Figure 13: Co-precipitation ofNEMO by nucleolin in AGR0100-treated cells. 
(A) Cytoplasmic (8-100) extracts were prepared from HeLa ceUs that had been treated 
for 1 h with 10 JlM AGR0100 (AGRO) or CR026 (CRO), then stimulated with TNFa 
for 30 min. Immunoprecipitation with nucleolin antibody was performed and western blot 
analysis was used to assess the presence of ~(J and nuc1e01in. Non-precipitated 
extract (5 Ilg) was used for comparison, in the left lane; (B) To confirm the interaction of 
NEMO and nucleolin in the absence of AGROlOO, a similar experiment was performed. 
Whole cell lysates from HeLa cells that were stimulated 30 min with TNFa were 
subjected to immunoprecipitation with anti-nuc1eolin antibody, and western blot analysis 
revealed the presence of NEMO and nucleolin, indicated by arrows. Mock 
immunoprecipitation (no ce11ular extracts, lane 3) and immunoprecipitation with non-
specific IgG were done in parallel to ensure the specificity of the interaction (lane 4). 
Non-precipitated extract (5 Jlg) was used for comparison (left lane). Non-specific bands 
that were artifacts ofthe immunoprecipitation are indicated by "'NS". 
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[136]. The components of the IKK complex are of particular interest for drug discovery 
[139] and peptide inhibitors of ~o have recendy been shown to have anticancer 
activity [145], in addition to anti-inflammatory properties [52]. 
We have now demonstrated that AGROlOO is an inhibitor of both constitutive and 
TNFa-induced NF-KB signaling in a variety of cancer cell lines derived from prevalent 
solid tumor types. Moreover, we have defined a probable mechanism of this activity by 
showing that AGROlOO sequesters NEMO in a complex with nucleolin, thereby 
preventing activation of IKK and precluding phosphorylation of IKBa and subsequent 
release ofNF-KB (Figure 14B). Although it has not been ascertained that the inhibition 
of NF-KB is responsible for the anticancer activity of AGROlOO, it seems likely that 
blocking this pro-survival, anti-apoptotic pathway in cancer cells that have constitutive 
activation would lead to antiprolit"erative etIects. it is apparent from Figures 9 and 12 that 
the ability of AGROlOO to inhibit TNFa-induced NF-KB signaling does not correlate 
directly with its antiproliferative activity. However, this is not surprising since TNFa is 
absent in the experiments shown in Figure 9 and the effects of inhibiting constitutive NF-
KB activity may depend complexly on numerous factors, including the basal level ofNF-
KB signaling and the extent of its inhibition by AGROlOO. It may be significant that 
AGRO 1 00 has the least growth inhibitory effect on Hs27 cells, which have no detectable 
constitutive activation of NF-KB (confirmed by an EMSA to detect NF-KB in 
unstimulated nuclear extracts). In any case, as discussed below, it appears that inhibition 
ofNF-KB signaling is one of several potential anticancer effects induced by AGRO 1 00. 
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Figure 14: Schematic representations ofNF-1CB activation and proposed model for 
its inhibition in the presence of AGR0100. 
(A) Upon ligation of an appropriate surface receptor, such as the TNFa receptor (TNFR), 
a signal is transduced to activate the IKK complex, which consists of IKKa, IKKf3 and 
NEMO. The complex then phosphorylates IKBa, which nonnally holds NF-KB in an 
inactive state in the cytoplasm, and causes it to become ultimately degraded by the 26S 
proteasome. Thus, the nuclear localization signal of NFKB is unmasked and the 
transcription factor trans locates to the nucleus to activate gene expression; (B) In the 
presence of AGROlOO, NEMO is sequestered in a complex containing nucleolin and 
AGROIOO. The IKK complex is therefore inactive and phosphorylation of IKBa cannot 
occur, which prevents release and activation ofNF-KB. 
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Nucleus 
Clearly, more research is needed to fully characterize the mechanism of GROs 
such as AtlltOH)(), but the resuits described herein are consistent with our theory that 
they work primarily as nucleolin-targeted aptamers. While investigating the role of 
nucleolin in GRO activity, we have observed by farwestem blotting that the presence of 
AtlltOW() can induce changes in the protein-protein interactions of nuc1eotin, which 
include some enhanced and some reduced interactions (unpublished observations). 
Therefore, our hypothesis regarding the mechanism of GROs is that their antiproliferative 
effects result from their binding to nuc1eotin and modu1ation of its molecular interactions. 
We predict that this consequently alters certain activities of this highly multifunctional 
protein, leading to pleiotropic biological effects. Such effects may include inactivation of 
NF-KB signaling, inhibition of DNA replication and induction of cell death, which have 
been reported here or previously [35]. We have now shown that AGROIOO inhibits NF-
KB activation by stabilizing a complex containing nucleolin and NEMo. Thus, we have 
identified NEMO as one of the partners ofnucleolin whose binding is affected (enhanced, 
in this case) by the presence ofAGROlOO. 
The complex interactions that regulate NF-KB signaling are an area of intense 
interest and much has been learned regarding these in recent years. However, the full 
details of the pathway, especiaUy the mechanisms leading to lKK activation, are not yet 
fully understood. Although nucleolin has not previously been implicated in NF-K13 
signaling, our present findings that a nuc1eolin-binding aptamer inhibits NF-KB activity 
and that nuc1eolin is associated with NEMO are suggestive of a role for nuc1eolin in 
regulation of the IKK complex. In conclusion, further studies appear to be warranted in 
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order to define the precise nature of the nucleolin-NEMO interaction and to determine the 
role ofnucleolin in NF-JCB signaling, which is further examined in Chapter 4. 
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CHAPTER IV 
NUCLEOLIN AND NEMO: POSSmLE ROLE FOR 
NUCLEOLIN IN NF-KB SIGNALING 
INTRODUCTION 
The Nli-KB/Rel fumily of transcription factors has intensively studied as an 
important model system tor how extracellular stimuli, such as tumor necrosis factor a 
(TNFa), cause the activation of transcription factors through signal transduction 
cascades. NF-KE regulates the expression of many genes critical for cellular processes, 
including inflammation, immune responses, and apoptosis [150]. NF-KB is normally 
kept inactive in the cytoplasm of unstimulated cells by its inhibitor proteins, IKEa. 
When an extracellular signal binds to the appropriate cell surface receptor, the signal 
results in the release of the NF-KE dimer from IKEa, and subsequent translocation to the 
nucleus to regulate gene transcription [110]. 
Central to the activation of NF-K8 by extracellular stimuli is the IKE kinase 
(IKK) complex. The IKK complex is composed of two catalytic subunits IKKa and 
IKKf3, and a regulatory subunit NEMO (NF-KE essential modulator). Signaling 
pathways lead to the activation of IKK, which then results in the phosphorylation of IKE 
and its degradation by the ubiquitin-proteosome pathways allowing the release ofNF-KE 
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[110]. NEMO is essential in regulating IKK and the activation ofNFK-B; its importance 
has been demonstrated in NEMO knockout mice experiments, where there is a complete 
loss ofNF-KB activity in response to stimuli [150]. NEMO has multiple distinct domains 
which are thought to be used as scaffolding for the binding of IKKa. and IKK(3, and 
possible binding of other unknown proteins as well [110]. 
Nucleolin is predominantly known as a nucleolar protein that is highly 
muitifunctiona1. This llO-kt'> protein has been impiicated in several ce11u1ar functions 
like cell growth and proliferation [40-42], ribosome biogenesis [40, 43], DNA replication 
[44], cytokinesis and nuclear division [45], and apoptosis [46,47]. Although nucleolin is 
generally thought of as a nuc1e01ar protein, there has been evidence supporting the rote of 
nucleolin in transporting proteins between the cytoplasm and nucleus [60-62], and 
several reports demonstrating the mobility of nucleolin in the nucleoplasm, cytoplasm, 
and ceii surface [34, 48-j3]. The translocation of nuc1eotin to the cett surface has been 
shown in response to stimuli such as heat shock [44, 54], T-ceil activation [55], mitosis 
[56], treatment with cyctin-dependent kinase inhibitor [57], and viral infection [58-60]. 
We report here that decreased expression of nucleolin by siRNA results in 
increased NF-KB transcriptional activity. Additionally, upon stimulation with TNFa., 
nucleolin and NEMO precipitate in the same complex in a time-dependent manner. 
These results suggest a possible role of nucleolin in the signaling cascade that leads to the 
transcription of genes regulated by NF-KB. 
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MATERIALS AND METHODS 
Cell culture and treatment 
HeLa ceils (cervical cancer ceUs) in were obtained from American Type Culture 
Collection (ATCC). Cells were grown to 50% confluence in 6-well plates in a standard 
incubator in DMEM (Gibco) supplemented with 10% heat-inactivated (65°C for 20 min) 
fetal bovine serum (Gibco), 100 units/ml penicillin and 100 units/ml streptomycin. 
TNFa. (R & D Systems, Inc.) was added to the culture medium for a final concentration 
of 10 ng/mt 
siRNA 
The siRNA duplex sequence is 5'-d(GUUOCAGCAGCClJlJCtJUGClJU)-J' (antisense) 
and 5'-d(GCAAGAAGGCUGCUGCAACUU)-3' (sense) (Oligos Etc.). The antisense 
and sense strands of siRNA were suspended in Diethyl-pyrocarbonate (DEPC)-treated 
water. All siRNAs were annealed at 90°C for 2 min, then 37°C for 1 hr in Buffer R (100 
mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate). HeLa 
cells were transfected with siRNA (100 nM) using Oligofectamine transfection reagent 
(Invitrogen) in tlpti-M:I:£M 1 reduced serum medium (1nvitrogen) according to 
manufacturer's instructions. Cells were lysed with the addition of M-PER Mammalian 
protein extraction buffer (pierce). 
Western blot analysis 
Whole cell lysates were electrophoresed on SDS-polyacrylamide (8%) gels and 
tfiiflsfeffed to P\t'DF memlniifles. lvfembfiifles were blocked with §% floofat dried milk :ift 
PBS plus 0.05% Tween20 (PBST) then incubated with primary antibody in PBST (1 
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Jlglml anti-nuc1eolin, sc-8031, Santa Cruz or 1 Jlglml anti-NEMO, sc-8032, Santa Cruz). 
Following incubation with secondary antibody (0.5 Jlg/ml anti-mouse HRP-conjugated, 
StlHttl Cruz) f>tlHtlS were vistitlii~etl by enemilumiHeseeHee (EeL, Amersnl:lffl 
Biosdences ). 
Transient transfection and measurement of luciferase activity 
Cells were plated in 24-well plates at a density of 2 x 104 cells per well and were 
!n!n~i~ntJy !mn~f~9!!t~ witb fin NF-~ r~P9r!~r p!a.smj~ img fin jn!~mfiJ 99ntml pl!!.smjg 
(described below) using Superfect reagent (Qiagen), according to the manufacturer's 
protocol. At 24 h post-transfection, the cells were treated with siRNA as described above. 
After an incubation of 48 h, TNFa (10 ng/ml) was added to the medium for an additional 
6 hand celllysates were prepared using reporter lysis buffer (Promega). Lysates were 
added to the substrate reagents supplied in the Dual-Luciferase reporter system 
(Promega) and luciferase activity was measured using a luminometer (Zylux 
corporation). The NF-Kl3 reporter plasmid contained tandem repeats of the KB sequence 
upstream of the minimal simian virus 40 (SV40) promoter and firefly luciferase gene in 
pLuc-MCS vector (Stratagene) and was a kind gift from Dr. Fajan Yang. As an internal 
control to account for variations in transfection efficiency, pRLnull (Promega), which 
expresses Renilla luciferase by basal transcription, was used (a gift from Dr. Robert 
Mitchell). Luciferase activity is expressed as the activity of firefly luciferase divided by 
Renilla lucif~r~. 
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Immunoprecipitation of NEMO 
HeLa cells were plated as described above and treated with TNFa (10 ng/ml) for various 
from 5 min to 180 min. Cells were lysed with the addition M-PER Mammalian protein 
extraction buffer (pierce). The extracts were incubated with 10 Jlg of anti-NEMO 
antibody (sc-8330, Santa Cruz) for 2 h at 4°C in RIPA buffer (150 mM NaCl, 10 mM 
Tris.Hcl pH 7.5, 0.1% SDS, 1% Triton X-100, 1% Deoxycholate, 5 mM EDTA, ImM 
PMSF, 2 Jlg/ml leupeptin). Protein G coated magnetic beads (Magnabind, Pierce) were 
then added to the samples and incubated for 1 h at 4°C. The beads were captured and 
unbound sample was removed by washing three times with RlPA buffer. The precipitated 
proteins were eluted from the beads by the addition of SDS sample loading buffer (4% 
SDS, 2% glycerol, 5% J3-mercaptoethanol, 0.75 M Tris.HCI, pH 8.8) and heating at 65°C 
for 15 min. Western blot analysis, as described above, was then utilized to detect the 
presence ofNEMO and nucleolin. 
RESULTS 
Decrease of nucleolin expression increases NF-lCB transcriptional activity 
HeLa cells were transfected with siRNA (100 nM) corresponding to nucleolin or a 
nonspecitIc sequence as a control. Following an incubation of 48 h, the cells were 
stimulated with TNFa (10 ng/ml) for 2 h, then lysed and subjected to western blot 
analysis to detect levels of nucleolin and J3-actin as a loading control. Sufficient 
knockdown of nucleolin was achieved as seen in Figure 15. To examine NF-KB 
transcriptional activity, HeLa cells were first transfected with a NF-KB luciferase reporter 
plasmid and a null renilla plasmid as an internal control. 24 h after transfection, the cells 
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were treated with siRNA as described above. Following stimulation with TNFa for 6 h, 
luciferase activity was measured revealing an increase in NF-K8 transcriptional activity 
in response to the knockdown of nucleolin. (Figure 15). 
Asscociation of nucleolin and NEMO increases in the presence of TNFa 
We previously observed co-precipitation of nucleolin and NEMO in the presence 
of GRO in the S-100 fraction of ceH lysates (see Chapter 3). This association suggested 
nucleolin may be involved in the signaling events leading to NF-K8 transcription. To 
examine this possibility, cells were treated with TNFa from 5 to 180 min. Cells were 
lysed and subjected to immunopreciptation with NEMO antibody. Western blotting 
revealed the association of nucleolin and NEMO increases in the presence of TNFa 
(Figure 16). 
Re-Iocalization of nucleolin in response to TNFa stimulation 
We then investigated the effects of stimulation with TNFa on the levels and localization 
of nucleolin. Western blot analysis of lysates from HeLa cells (Figure 17) revealed an 
increase in 8-100 nucleolin and a concomitant reduction in nuclear nucleolin, suggesting 
that there is rapid translocation of nucleolin in response to TNFa. 
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Figure 15: Decreased expression ofnucleolin results in increased NF-ldJ 
transcriptional activity. 
(A) Western blot analysis probing for nucleolin and p-actin from celllysates transfected 
with siRNA (100 nM) corresponding to nucleolin or a non-specific sequence then 
stimulated with TNFa. (10 nglml); (B) NF-KB transcriptional activity in the presence of 
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Figure 16: Association of nucleolin and NEMO increases in the presence of TNFa. 
HeLa cells were treated with TNFa (10 ng/ml), lysed, and subjected to 
immunopreciptiation with NEMO antibody.- Western blot anlaysis revealed the presence 
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Figure 17: Translocation of nucleolin in response to TNFa stimulation. 
Nuclear and S-100 fractions were prepared from HeLa cells that had been stimulated with 
TNFa (10 ng/ml) for the time indicated. These extracts were subjected to western blot 
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DISCUSSION 
There has been a lot of interest in NF-lCB signaling recently due to its involvement 
in several cellular processes. Although research has revealed much information about the 
events leading to NF-lCB transcription, there are still unanswered questions in the 
signaling cascade, especially in the activation of the IKK complex. 
We report here that nucleolin may playa role in the signaling cascade of NF-KB 
transcription; although there needs to be additional research to validate this hypothesis, 
we show evidence suggesting that nucleolin may be involved in the signaling cascade. 
Down-regulation of nucleolin by siRNA results in an increase in NF-KB transcriptional 
activity (Figure 15). Additionally, the association of nucleolin and NEMO increases in 
the presence ofTNFa. in a time-dependent manner (Figure 16), and nucleolin translocates 
in response to TNFa. (Figure 17). This evidence suggests nucleolin may playa role in the 
activation ofIKK 
There has been no previous reports describing the interaction of nucleolin and 
NEMO in NF-lCB signaling; there is other circumstantial evidence supporting a role in 
this pathway. For example, it has been reported that nuc1eolin is phosphorylated in 
response to TNFa. [151], and several other stimuli known to activate NF-lCB can also 
induce mobilization ofnucleolin [47,55]. Nucleolin is a protein that shuttles between the 
nucleus and cytoplasm [50], and NEMO also undergoes nucleocytoplasmic shuttling 
[150]. Because ofthe NEMO-nucleolin colocalization in response to TNFa., it is possible 
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that nucleolin may be involved in its trafficking. In conclusion, further studies are 
needed to identifY the role of nuc1eolin in NF-1d3 signaling and the interaction between 
nuc1eolin and NEMO. 
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CHAPTER V 
GLOBAL ASSESSMENT OF GENE AND PROTEIN EXPRESSION 
IN CELLS TREATED WITH 
GUANINE-RICH OLIGONUCLEOTIDES 
INTRODUCTION 
Cancer is a major pubiic heaith probiem in the United States being the second 
leading cause of death after heart disease. Currently, one in four deaths in the United 
States is due to cancer [66]. Although there have been improved screening and treatment 
regimens, there is stiit a need for novel therapies in patients that do not respond to the 
treatment and for those patents who develop resistance to traditional chemotherapy. 
We have previously described a novel therapy known as guanine-rich 
otigonuc1eotides (ti"ROs). tiROs contain sequences that are capable of forming ti-
quartets, which are four coplanar guanines stabilized with Hoogsteen hydrogen bonds. 
They exhibit potent antiproliferative properties in several malignant cell lines, inducing 
3-phase ceil cycle arrest and ce11 death exc1usive1y in cancer celts, teaving non-maiignant 
cells primarily unaffected [35]. GROs have also demonstrated considerable potential in 
phase I clinical trials in patients with advanced cancer, showing that the drug is well 
tolerated and exhibits promising cHnical activity [38]. The primary target of CJ"ROs has 
previously been identified as nucleolin [34], which is a multifunctional protein involved 
in a variety of cellular processes like ribosome biogenesis [40,43], DNA replication [44], 
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cell growth and proliferation [40-42], apoptosis [46, 47], and cytokinesis and nuclear 
division [4j]. Nucie01in can also function as a ce11 surface receptor, where it acts as a 
shuttling protein between cytoplasm and nucleus [60-62]. 
Recent advances in high-throughput differential gene expression technologies 
have revolutionized research. The abitity to obtain expression data for tens of thousands 
of genes from the same sample in a single assay has made it possible to study 
complicated interactions between networks of genes and gene products [146, 147]. 
Although much insight can be gained nom analyzing giobal gene expression, this 
approach is limited in that it fails to monitor posttranscriptional mechanisms; so it 
imperative to investigate global protein expression as well [148]. 
In this study, we applied cDNA microarray and two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE) technologies to analyze malignant cells that have treated 
with filtOs. We propose that the use of combined globat gene and protein expression 
technologies will allow for a better understanding of the mechanism of GROs. Although 
these techniques generate excessive data, our results reveal important aspects into the 
antiprotiferative properties of altOs. 
MATERIALS AND METHODS 
Cell culture and treatment 
DU145 cells (prostrate cancer cells) in were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were grown to 50% confluence in a standard 
89 
incubator in DMEM (Gibeo) supplemented with 10% heat-inactivated (65°C for 20 min) 
fetal bovine serum (Gibeo), 100 units/ml penicillin and 100 units/ml streptomycin. The 
cells were then treated by addition of oligonucleotide directly to the culture medium to 
give the final concentration of 10 J.lM. The oligonucleotides used in these experiments 
were as follows: GR026B, 5'-d(GGTGGTGGTGGTTGTGGTGGTGGTGG)-3', and an 
inactive control CRO, 5' -d(CCTCCTCCTCCTTCTCCTCCTCCTCC)-3'. The 
oligonucleotides were purchased in the desalted form from Integrated DNA Technologies 
Inc. and used without further purification. They were then resuspended in water, 
sterilized by filtration through a 0.2 J.lm tIlter, then diluted with sterile water to give stock 
solutions of 400-500 J.lM that were stored in aliquots at -20°C. 
Preparation of labeled cRNA, array hybridization, and global gene analysis 
DU145 cells were grown to 50% confluence in T150 culutre flasks and samples were 
prepared from cells that were untreated or treated with GR026B (10 J.1M) or CRO (10 
J.lM) for either 2 h or 18 h. Total RNA was isolated from the cells with Trizol reagent 
(Invitrogen) according to manufacturer's protocol. Subsequent mRNA isolation was 
done using an mttNA purification kit (Qiagen) using the instructions provided by the 
manufacturer. The protocols for sample preparation are described in the Affymetrix 
technical manuaL But briefly, mRNA was converted to double-stranded cDNA using 
Superscript Reverse transcriptase (Invitrogen) and an o1igo(d1') primer tinked to the 1'7 
RNA polymerase-binding sequence. The cDNA was then converted to labeled cRNA 
using T7 RNA polymerase in the presence of biotinylated UTP and CTP (ENZO 
Viagnostics). lhe 1abe1ed cttNA was purified with an ttNeasy coiumn (Qiagen), and 
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fragmented by heat and ion-mediated hydrolysis. The fragmented cRNA was hybridized 
for 16 h at 45°C to Affymetrix GeneChip Human HG_U133, followed by washing, 
staining, signal amplification with biotinylated antistreptavidin antibody, and final 
staining. The array was then scanned using a laser confocal genearray scanner, and the 
scanned images were analyzed using Affymetrix Analysis Suite 4.tl. The differences in 
the levels of fluorescence intensity, representing the levels of hybridization, were 
analyzed by multiple stringencies to determine the alterations in levels of gene 
expression. aackground and noise corrections were made to account for nonspecific 
binding and minor variations in hybridization conditions. The online data mining tool, 
NetAffx Analysis Center (Affymetrix), was then used to analyze to the results. 
Sample preparation and protein separation by 2D electrophoresis 
DU145 cells were grown to 50% confluence and treated with 10 J..lM GR026B, CRO, or 
left untreated as a control. After 4 or 24 h of treatment, nuclear and S-100 extracts were 
isolated with ReadyPrep Protein Extraction Kit (Bio-Rad) according to the 
manufacturer's protocol. To ensure the lysates were suitable for 2D electrophoresis, the 
extracts were subjected to tteadyt>rep 20 Cleanup Kit (aio-ttad) fo11owing the protocol 
provided by the manufacturer. Samples (lOa J..lg) were run on non-linear pH 3-10 LPG 
strips (Invitrogen) for the first dimension. The proteins were then run on 4-12% gradient 
acrytamide gets (tnvitrogen) for the second dimension. tto11owing etectrophoresis, the 
gels were visualized with colloidal Coomassie blue stain (Genomic Solutions). 
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RESULTS 
Microarray analysis reveals many genes affected by treatment with GAO 
Microarray chip analysis was used to investigate alterations in global gene 
expression in cells treated with GRO. DU145 cells were treated with active GRO, 
inactive ett(J, or left untreated for mRNA extraction after 2 and 18 h of treatment. The 
samples were prepared and subjected to microarray chip analysis to reveal alterations in 
the global gene expression of the cells treated with GRO compared to eRO treated and 
untreated ce11s. The analysis reveated 63 genes a1tered after only 2 hours of treatment 
with GRO, and 238 genes altered after 18 hours of treatment with GRO. Tables 3 and 4 
list the genes altered by treatment with GRO, and their fold changes relatives to the 
controls. 
Although the expression of these genes needs to be validated by another 
technique, such as "R't'-pCtt, there are some interesting observations that can been seen in 
the global expression data from cells treated with GROs. One observation is the 
expression of nucleolin is not affected by treatment with GROs. Because nucleolin is the 
primary target of (J"R(Js [34], it is important to note that (J1t(Js apparentty do not 
influence the transcription of nucleolin which is consistent with previous work indicating 
that total levels of nucleolin protein are not changed in GRO-treated cells. This 
observation leads to two tikely possibliities: either G1t(Js are affecting the function of 
nucleolin directly, or nucleolin binds to GROs on the surface of the cell, and aids in 
shuttling the GRO inside the cell where it affects function of other proteins. 
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There are several other observations that can be seen from the global gene 
expression data. There are several changes in metabotic enzymes, particularly those 
involved in tatty acid and glycerolipid metabolism. These include the expression of 
acetyl coA carboxylase (-8.9), g-butyrobetaine hydroxlyase (-4.6), NADH ubiquinone 
oxidoreductase (-4.9), and NAt) synthetase (-2.1). There is also a marked decrease in 
expression in many cancer-associated proteins including telomerase (-5.7), estrogen 
receptor a (-8.0), cathespin S (-4.4), and EpCAMffROP2 tumor marker (-20.5). A 
strong induction can be seen in RUSI checkpoint analog (+ 15.6), which is a cell cycle 
checkpoint protein. There is also a dramatic decrease in specitic transcription factors 
such as T-box 1 (-78.8), achaete-schute-like 2 (-27.3), and single minded 2/SIM2 (-12.4). 
A strong induction of severa1 heHcases can be observed inc1uding t>OX3X (+13.3), 
SMARCAl (+ 10.1), DDX17 (+4.4), and RecQ-iike helicase (+2.2). 
Microarray analysis reveals many biological systems affected by treatment with 
GRO 
Upon further analysis, the affected genes are involved in several different cellular 
functions. Tables 5 and 6 lists these biological processes, the number of genes involved 
in the processes, and the number of tl1tc>-a1tered genes in each process. After two hours 
of treatment with ORO, there are several biological processes affected including 
transcription, transport, and metabolism, particularly nucleic acid metabolism. ORO 
treatment for 18 hours ieads to the aiteration of many more ce11ular functions. The same 
processes seen after two hours of treatment are also seen after 18 hours, with the addition 
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of many more affected cellular functions. These functions include signal transduction, 
ce11 communication, apoptosis, ce11 motiifty, ceil adhesion, programmed ceil death, and 
regulation of cell growth. 
Alterations in global protein expression in GRO treated cells 
DU145 cells were treated with 10 J.1M GR026B, eRO, or left untreated as a 
control. After 4 or 24 h of treatment, nuclear and S-100 extracts were isolated and 
subjected to separation by 2D electrophoresis. The individual proteins were then 
visuaHzed by co11oidal eoomasie stain. As seen in ttigures 18 and 19, globa1 protein 
expression does not appear to be greatly affected by treatment with GRo. We do expect 
to see the expression of several proteins affected, given that the global gene expression 
shows several genes affected by the ORO. This is most Hkely due to the sensitivity of 
this technique which limits the detection of these proteins. Using this technique, 63 
nuclear and 41 cytoplamsic proteins were visualized, which is clearly not representative 
of the entire ce11u1ar proteome. 't'heretbre, further investigation is needed to explore the 
global protein expression affected by GROs. 
DISCUSSION 
The success of the genome project and technological advances in functional 
genomics and proteomics has facilitated the transition to large-scale systemic approaches 
in studying global mechanisms. mRNA expression profiling by microarray has been 
used in a wide range of cancer-related studies and provided important insights into 
disease. More recently, proteomic analysis by 2D electrophoresis and mass spectrometry 
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have provided additional clues about the post-transcriptional mechanisms underlying 
disease. Utitizing these techniques can give significant insight in investigating ce11ular 
mechanisms on the global scale [148]. 
We have previously reported guanine-rich oligonucleotides (GROs) exhibiting 
potent antiproHfurative properties in several ma1fgnant ce11 tines [34-37], and 
demonstrating considerable potential as a novel therapeutic agent for cancer [38]. 
Although some important aspects of GRO activity are known (i.e. S phase cell cycle 
arrest and ce11 death) [35], the precise moiecuiar mechanism remains unc1ear. However, 
it is known that the activity of GROs correlate with its ability to bind to nucieolin, and 
there is evidence to support that nucleolin is the primary target of GROs [34]. 
The goal of this study is to gain a better understanding of the mechanism of GRO 
antiproliferative activity by utilizing global gene and protein expression technologies. 
Unfortunately, the 1tl e1ectrophoresis used to detect giobal protein expression in cel1s 
treated with GROs was not able to detect any alterations in the proteins isolated, probably 
due to the sensitivity of the technique. However, microarray analysis revealed the 
expression of several genes changed upon treatment with OROs. After only two hours of 
treatment with GROs, the cell responds by increasing or decreasing the expression of 63 
different genes, and 238 genes after 18 hours oftreatrnent (Tables 3 and 4). These genes 
are involved in a variety of ce11u1ar functions (Tabies 5 and 6), the most prominent being 
metabolism, transcription, and transport. 
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Microarray analysis also revealed that the expression of nucleolin did not change 
in the cet1s treated with <J'KC>. 13ecause nuc1eotin is presumably the primary target of 
GROs [34], it is most likely that GROs either modify the function of nucleolin directly, 
or nuceolin shuttles the GRO inside the cell where it affects the function of other 
proteins. Nucleotin is an abundant protein that is implicated in several different ce11uiar 
functions. Interestingiy, some of the same functions that are affected by GROs have been 
implicated in the function of nucleolin; these include transcription [42], apoptosis [46, 
47], heticase activity (42], and regulation of ceti growth [46-42l This evidence is 
consistent with our hypothesis that GROs directly affect the function of nucleolin; 
however it appears that GROs are not exclusively affecting nucleolin. Because of the 
abundance of genes and functions aitered by treatment with tlKOs, it appears that the 
functions of proteins other than nucleolin are altered as wen. 
Clearly, more work is needed to decipher the molecular mechanism of the 
antiprotiferative activity of tlKt>s. in this present study, we have gained insight into how 
the cell responds to GRO treatment by utiiizing microarray technology. The results 
presented here are only a foundation in which to continue the investigation into the 
mechanism of tlKt>s. Other tecfmiques shouid be utitized to vaiidate the expression 
changes seen in the microarray data. Additionally, it is important to investigate the 
expression levels of proteins as well since posttranscriptional modifications can alter a 
presumed function of a gene. However, our results are a notable starting point in which 
to continue research. 
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l:kn'110 sapiens clor.e 24540 mRNA sequar.ce 
RAB9, member RAS oncogene family, pseudogene 1 
nuclear antigen Sp100 
EGF-like repeats and discoidin I-like domains 3 
KIAA 1068 protein 
Homo sapiens mRNA; cDNA DKFZp434J193 (from clone DKFZp434J193); partial 
cds 
thymus high mobility group box protein TOX 
HIV-1 inducer of short transcripts binding protein 
ADP-ribosylation factor interacting protein 1 (arfaptin 1) 
likely ortholog of mouse and zebrafish forebrain embryonic zinc finger-like 
I factor (complement) 
'fAr6-1ike RNA polymerase II, p300/eBP-associated factor (peArt-associated 
factor, 65kDa 
21383_at 
hypothetical protein MGC 11266 
hypothetical protein FLJ11142 
macrophage stimulating, pseudogene 9 
hypothetical protein FLJ32389 
leukocyte Ig-like receptor 9 
216688_at 
zinc finger protein, Y -linked 
hypothetical protein FLJ13646 
e.ukaryotic translation initiation fact.or 4E 
APG12 autophagy 12-like (S. cerevisiae) 
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) 
polymerase delta interacting protein 46 
F-box and WD-40 domain protein 18 
amiloride binding protein 1 (amine oxidase (copper-containing» 
RNA binding motif protein 3 
CD34 antigen 
nescient helix loop helix 2 
211074_at 
transient receptor potential cation channel, subfamily A, member 1 
protein tyrosine phosphatase type IVA, member 2 
hypothetical protein MGC3067 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), 
memberA3 
superoxide dismutase 2, mitochondrial 
calponin homology (QH) domain containing 1 
acetyl-Coenzyme A carboxylase alpha 
8-ce1l CLUlymphoma 7C 
chromosome 6 open reading frame 11 
protein kinase C and casein kinase substrate in neurons 3 
chromosome 14 open reading frame 34 
peptidylproly1 isomerase (oyGlophilin)-like 2 
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-2.8 autoantigen 
-2.7 cholinergic receptor, nicotinic, epsilon polypeptide 
-2.; keratin 15 
-2.4 hypothetical protein MGC5178 
-2.3 hypothetical protein 24432 
-2.3 transmembrane 4 superfamily member 7 
-2.2 hypothetical protein FLJ22341 
-2.2 host cell factor C1 regulator 1 (XP01 dependant) 
-2.2 7 -dehydrocholesterol reductase 
-2.2 transmembrane 7 superfamily member 2 
-2.1 pleiomorphic adenoma gene-like 1 
-2.1 proline dehydrogenase (oxidase) 1 
-2.1 PISC domain containing hypothetical protein 
-2.1 inhibitor of DNA binding 2, dominant negative helix:-!ccpd'>.elix protein 
-2.1 jagged 2 
-2.1 hepatitis delta antigen-interacting protein A 
-2.1 stearoyl-CoA desaturase (delta-9-desaturase) 
-2.0 filamin B, beta (actin binding protein 278) 
-2.0 hypothetical protein FLJ21347 
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Table 4: Genes altered after 18 hours of GRO treatment. 
100 
Fold 
change Gene title 
15.6 I:IUS1 ct'.ackpoint r.omolog (S. pomba) 
14.5 hypothetical protein FLJ10849 
13.5 hypothetical protein FLJ10970 
13.2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
10.9 EGF-like repeats and discoidin I-like domains 3 
SWIISNF related, matrix associated, actin dependent regulator of chromatin, 
10.1 subfamily a, member 2 
8.0 hypothetical protein PR01853 
6.5 PTB domain adaptor protein CED-6 
6.2 SEC10-like 1 (S. cerevisiae) 
5.9 v-rel reticuloendotheliosis viral oncogene homolog (avian) 
5.5 glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease 1110) 
€i.a RAB3B. member RAS OI1oogene family 
5.4 golgi SNAP receptor complex member 2 
5.2 zinc finger protein 37a (KOX 21) 
5.2 hypothetical protein FLJ12994 
5.1 prenylcysteine oxidase 1 
5.0 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
4.9 actin filament associated protein 
4.9 wingless-type MMTV integration site family, member 7B 
4.4 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
4.3 zinc finger RNA binding protein 
4.1 paraneoplastic antigen 
4,1) PTK~ pr9t~in tym~in~ kina-~ ~ 
3.8 211506_s_at 
3.7 216383_at 
3.6 similar to Caenorhabditis elegans protein C42C 1. 9 
guanine nucleotide binding protein (G protein), alpha activating activity polypeptide, 
3.5 olfactory type 
3.4 suppression of tUll'.origenicity 
3.3 Homo sapiens cDNA FLJ31439 fis, clone NT2NE2000707. 
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death 
3.3 domain 
3.2 ring finger protein 125 
3.1 fumarate hydratase 
3.1 stfess-iRdueea-iiRespl'l6j:lfeteiR 1 (Hsp70iHsp90-eF~aRi;ziR~ preteiR) 
3.1 zinc finger RNA binding protein 
3.1 NGFI-A binding protein 1 (EGR1 binding protein 1) 
3.0 paternally expressed 10 
3.0 poly(A) polymerase alpha 
3.0 steroid sulfatase (microsomal), aryl sulfatase C, isozyme S 
3.0 Homo sapiens, clone IMAGE:5294815, mRNA 
2.9 secretory carrier membrane protein 1 
2.9 endothelial and smooth muscle cell-derived neuropilin-like protein 
2.8 aryl hydrocarbon receptor nuclear translocator-like 2 
2.8 208844_at 
2J~ m~t pmt9-9n~~n~ (h~mQ~yt~ gr9Wth fa~Qf r~ptQf) 
2.8 SOCS box-containing WD protein SWiP-1 
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2.8 PCTAIRE protein kinase 2 
2.7 vesicle-associated membrane protein 3 (cellubrevin) 
2.7 Bel-2-asseeiated tf8f\sefipti6R faetef 
2.7 cyclin E2 
2.7 hypothetical protein H41 
2.6 cell division cycle 27 
2.6 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
2.6 NDRG family member 3 
2.S progesterone receptor membrane component 1 
2.S mitogen-activated protein kinase kinase kinase kinase S 
2.S zinc finger protein 426 
2.5 secretory carrier membrane protein 1 
2.S heat shock 70kDa protein 4 
2.5 APG12 ~1.,!tQP.Mgy 12-like (S. ~-erevisj~e) 
2.S CD164 antigen, sialomucin 
2.S AFFX-r2-Hs18SrRNA-M_x_at 
2.4 REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 
SWIISNF related, matrix associated, actin dependent regulator of chromatin, 
2.4 subfamily a, member 2 
2.4 zinc finger protein.45 (Q I(ruppel.,.QssociQtGd box (I(RAB) domQin pol;'PQptidQ) 
2.4 septin 10 
2.4 Homo sapiens hypothetical LOC133993 (LOC133993), mRNA 
2.4 Sec23 homolog A (S. cerevisiae) 
2.4 polymerase (RNA) III (DNA directed) (32kD) 
2.4 hypothetical protein KIAA 1164 
2.3 histone 1, H3t'l 
2.3 Ras-GTPase activating protein SH3 domain-binding protein 2 
2.3 RIO kinase 3 (yeast) 
2.3 interleukin 6 signal transducer (gp130, oncostatin M receptor) 
2.3 HIV-1 Rev binding protein 
2.3 hypothetical protein MGC3067 
2.3 calumenin 
2.3 SEC24 related gene family, member D (S. cerevisiae) 
2.3 core-binding factor, beta subunit 
2.3 insulin-like 5 
2.3 AFFX-HUMRGElM10098_S_at 
2,2 ~mt1rQ91!Jil rn!Jilrnpr~n,!Jil prQtfljn, ~n,Q 4,1-ljk~ 1 
2.2 calumenin 
2.2 butyrate-induced transcript 1 
2.2 hypothetical protein MGC11061 
2.2 lectin, mannose-binding, 1 
2.2 NCK-associated protein 1 
2.2 ReeQ ptGteiR-like (DNA heiisalie Ql-1ike) 
2.2 chromosome 20 open reading frame 30 
2.2 secretory carrier membrane protein 1 
2.2 chromosome 6 open reading frame 62 
2.2 AFFX-HUMISGF3A1M9793S_MA_at 
2.1 calnexin 
2.1 muscleblind-like (Drosophila) 
2.1 SB8126 protein 














































-I t. 1 
-11.0 
-10.8 
GM2 ganglioside activator protein 
oculocerebrorenal syndrome of Lowe 
6atalase 
nucleolar and spindle associated protein 1 
Homo sapiens eDNA FLJ35853 fis, c~one TEST12007078, highly similar to 
MEMBRANE COMPONENT, CHROMOSOME 17, SURFACE MARKER 2. 
DKFZP586N0721 protein 
cleavage and polyadenylation specific factor 5, 25 kDa 
leukooyte-derived arginine aminopeptidase 
transducin (beta)-like 1X-linked 
hypothetical protein MGC14799 
ROD1 regulator of differentiation 1 (S. pombe) 
promethin 
phosphoglycerate kinase 1 
M-phase phosphoprotein, mpp8 
RIO kinase 3 (yeast) 
thioredoxin domain containing 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 3 
tumor rejection antigen (gp96) 1 
PTQQ19 p.rQt~i!1 
Homo sapiens transcribed sequence with weak similarity to protein ref:NP _060312.1 
(H. sapiens) hypothetical protein FLJ20489 [Homo sapiens] 
216899_s_at 
AFFX-HUMRGElM10098_M_at 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), 
memberA3 
• , , " ••• OM "" ~ ... 
lamina-associated polypeptide 1 B 
hypothetical protein FLJ12806 
Homo sapiens transcribed sequence with strong similarity to protein ref:NP _055485.1 
(H. sapiens) basic leucine-zipper protein BZAP45; KlAAOOO5 gene product [Homo 
sapiens} 
~g~!1Qyiry~ ~ J:1A pjrg;ng PfQtein 
solute carrier family 16 (monocarboxylic acid transporters), member 1 
serum/glucocorticoid regulated kinase-like 
T-box 1 
semenogelin II 
achaete-scute complex-like 2 (Drosophila) 
hypothetical protein LOC1 i7se7 
tumor-associated calcium signal transducer 2 




single-minded homolog 2 (Drosophila) 
217451_at 
EphA5 
Homo sapiens transcribed sequence with weak similarity to protein ref:NP _060219.1 
(H.sapiens) hypothetical protein FLJ20294 [Homo sapiens} 
217093_at 
supeiOxide dismutase 2, mitoohondiial 
insulin-like growth factor 1 (somatomedin C) 
Homo sapiens transcribed sequence with moderate similarity to protein 
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ref:NP _060219.1 (H. sapiens) hypothetical protein FLJ20294 [Homo sapiens] 
-10.1 Homo sapiens transcribed sequences 
-9.8 histamine receptor H3 
-9.5 alkaline phosphatase, placental-like 2 
-9.4 G protein--coupled receptor 17 
-9.4 cardiac ankyrin repeat kinase 
-8.6 dachshund homolog (Drosophila) 
-8.4 A kinase (PRKA) anchor protein 5 
-8.3 ankyrin repeat domain 1 (cardiac muscle) 
-8.1 estrogen receptor 1 
-8.0 tight junction protein 3 (zona occludens 3) 
-7.6 transmembrane protease, serine 4 
-7.6 cold autoinflammatory syndrome 1 
-7.S glutathione S-transferase t.'1eta 2 
-7.2 glutamate receptor, ionotropic, N-methyl D-aspartate 1 
-7.1 hypothetical protein FLJ10786 
-6.8 CD1E antigen, e polypeptide 
-6.6 zinc finger protein 157 (HZF22) 
-6.6 Homo sapiens cDNA: FLJ21911 fis, clone HEP03855 
-6.5 hypothetical protein FLJ22G88 
-6.5 tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) 




-5.9 small muscle protein, X-linked 
-5.8 zinc finger protein 254 
-5.7 cadherin, EGF LAG seven-pass G-type receptor i (flamingo homoiog, Drosophila) 
-5.7 telomerase reverse transcriptase 
-5.5 Nef associated protein 1 
-9.4 g!y.:;.gprQt~in, It? (Q'~t~I~t), ~ta PQ!y~pti~ 
-5.1 a disintegrin and metalloproteinase domain 28 
-4.9 high density lipoprotein binding protein (vigilin) 
-4.9 NADH:ubiquinone oxidoreductase MLRQ subunit homolog 
-4.8 S-hydroxytryptamine (serotonin) receptor 2C 
-4.7 family with sequence similarity 12, member B (epididymal) 
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine 
-4.6 hydroxylase) 1 
-4.5 tripartite motif-containing 3 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
-4.4 (semaphorin) 3F 
-4.4 211218_at 
-4.4 cathepSin S 
-4.1 homeo box 03 
-4.1 FK506 binding protein 12-rapamycin associated protein 1 
-3.9 217311 at 
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman 
-3.8 syndrome) 
-3.7 dystrophin (muscuiar dystrophy, Duchenne and Becker types) 
SWIISNF related, matrix associated, actin dependent regulator of chromatin, 
-3.7 subfamily at member 4 
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-3.7 tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 
-3.7 aquaporin 4 
-3.6 fef't<heaa bej( 03 
-3.5 homeo box A6 
-3.4 adipose specific 2 
-3.4 T -cell leukemia. homeobox 2 
-3.4 caspase recruitment domain family, member 10 
-3.3 ribosomal protein S11 
-3.3 agouti signaling protein, nonagouti homolog (mouse) 
-3.3 arginine vasopressin receptor 2 (nephrogenic diabetes insipidus) 
-3.2 diacylglycerol kinase, epsilon 64kDa 
-3.0 eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa 
-3.0 Homo sapiens transcribed sequences 
-2.9 grfJl1zyme A !grfJl1zyme 1. cytQ!Qxic T-lymphQcyte-a§§Qc!fJteg §eril1e es!erfJ§e 3) 
-2.8 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 
-2.8 G protein-coupled receptor 8 
-2.8 potassium inwardly-rectifying channel, subfamily J, member 12 
-2.8 histone 1, H4f 
-2.8 leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 5 
-2.7 Homo sapiens transcribed sequences 
-2.7 chromodomain helicase DNA binding protein 3 
-2.7 solute carrier family 22 (organic anion/cation transporter), member 11 
-2.7 221018_s_at 
-2.6 ATPase, H+ transporting, lysosomal9kDa, VO subunit e 
-2.6 fibroblast growth factor 18 
-2.6 LOC92346 
-2.6 Homo sapiens transcribed sequences 
-2.6 prostaglandin 02 synthase 21 kDa (brain) 
-2.5 KIAA1922 protein 
-2.5 hypothetical protein LOC339047 
-2,~ IMP !inQ§jn~ mQnQPhQ§ph~t~) g~ygrQgen~~ 2 
-2.5 Homo sapiens mRNA; cDNA DKFZp564P142 (from clone DKFZp564P142) 
-2.4 transient receptor potential cation channel, subfamily C, member 3 
-2.4 zinc finger protein 165 
-2.3 camitine palmitoyltransferase 1B (muscle) 
-2.3 tripartite motif-containing 31 
-2.3 221720 s at 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), 
-2.3 member 1 
-2.2 mitogen-activated protein kinase 8 interacting protein 3 
-2.2 cholinergiC receptor, nicotinic, epsilon polypeptide 
-2.2 chorionic somatomammotropin hormone-like 1 
-2.2 UD? ylyoosyltfBflsferase 2 family, pelyp9ptiEfe 817 
-2.2 viperin 
-2.2 hypothetical protein FLJ12443 
-2.2 calponin homology (CH) domain containing 1 
-2.2 growth differentiation factor 11 
-2.1 calcium channel, voltage-dependent, L type, alpha 18 subunit 
-2.1 C084 antigen (leukocyte antigen) 
-2.1 cysteine knot superfamily 1, BMP antagonist 1 
-2.1 NAD synthetase 1 
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-2.1 growth arrest and DNA-damage-inducible, beta 
-2.1 ribosomal protein L 17 
-2.1 Ry-pethetieal preteiA HSPC109 
-2.0 chromosome 12 open reading frame 6 
-2.0 CDC28 protein kinase regulatory subunit 1 B 
-2.0 interleukin 24 
DEAD/H (Asp-Glu-AJa-Asp/His) box polypeptide 11 (CHL 1-1ike helicase homolog, S. 
-2.0 cerevisiae) 
-2.0 E4f transcription factor 1 
-2.0 protocadherin beta 8 
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Table 5: Biological processes that are associated with genes altered by treatment 






pyrimidine nucleotide-sugar transport 1 5 20.0% 
nucleotide-sugar transport 1 5 20.0% 
cell proliferation 2 1341 0.1% 
lipid metabolism 2 578 0.3% 
induction of programmed ceii death 1 '173 0.6% 
programmed cell death 2 512 0.4% 
organic acid biosynthesis 1 56 1.8% 
cell activation 1 67 1.5% 
regulation of cell proliferation 1 366 0.3% 
regulation of endQaytosis 1 2 50,0% 
cell cycle arrest 1 71 1.4% 
response to oxidative stress 1 44 2.3% 
sexual reproduction 1 182 0.5% 
cation transport 1 454 0.2% 
ion transport 2 625 0.3% 
transport 5 1853 0.3% 
cell organization and biogenesis 2 632 0.3% 
carboxylic acid metabolism 2 394 0.5% 
regulation of protein biosynthesis 1 25 4.0% 
cell cycle 2 872 0.2% 
translational initiation 1 79 1.3% 
protein biosynthesis 1 565 0.2% 
T-cell activation 1 31 3.2% 
regulation of biosynthesis 1 49 2.0% 
histogenesis 1 129 0.8% 
organogenesis 3 1090 0.3% 
oxygen and reactive oxygen species metabolism 1 61 1.6% 
lymphocyte activation 1 59 1.7% 
neurogenesis 1 492 0.2% 
ectoderm development 1 95 1.1% 
vesicle-mediated transport 1 325 0.3% 
prOline metabolism 1 3 33.3% 
transcription from Pol II promoter 1 671 0.1% 
epidermal cell differentiation 1 2 50.0% 
hair cell fate commitment 1 2 50.0% 
non-covalent chromatin modification 1 48 2.1% 
immune response 1 903 0.1% 
defense response 1 963 0.1% 
response to stress 1 972 0.1% 
physiological process 25 10507 0.2% 
protein metabolism 5 2584 0.2% 
negative regulation of endocytosis 1 1 100.0% 
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cytoplasm organization and biogenesis 1 355 0.3% 
carbohydrate transport 1 26 3.8% 
reguiation of transcription from Poi II promoter 1 360 0.3% 
regulation of transcription, DNA-dependent 7 2120 0.3% 
transcription initiation 1 59 1.7% 
transcription, DNA-dependent 7 2262 0.3% 
transcription 7 2313 0.3% 
carboX'/lic acid bios}'Ot'1esls 1 56 1.8% 
central nervous system development 1 120 0.8% 
N signaling pathway 1 3 33.3% 
amine metabolism 2 295 0.7% 
cell fate commitment 1 11 9.1% 
microtubule-based movement 1 39 2.6% 
microtubule-based process 1 94 1.1% 
chromatin modification 1 90 1.1% 
protein ubiquitination 1 15 6.7% 
cytoskeleton organization and biogenesis 1 237 0.4% 
hearing 1 100 1.0% 
glutamine family a.mino acid metabolism 1 44 2.3% 
regulation of cell cycle 1 505 0.2% 
muscle c.ontraction 1 208 0.5% 
siderochrome transport 1 197 0.5% 
sensory perception 1 327 0.3% 
positive regulation of programmed cell death 1 173 0.6% 
endocytosis 1 144 0.7% 
regulation of programmed cell death 1 173 0.6% 
morphogenesis 3 1210 0.2% 
positive regulation of apoptosis 1 173 0.6% 
T-cell differentiation 1 13 7.7% 
cholesterol biosynthesis 1 26 3.6% 
cell surface receptor linked Signal transduction 1 1095 0.1% 
steroid biosynthesis 1 62 1.6% 
signal transduction 2 2915 0.1% 
chromatin remodeling 1 48 2.1% 
chromosome orga.'1ization and biogenesis (sensu Eukarya) 1 256 0.4% 
macromolecule biosynthesis 3 885 0.3% 
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 9 3310 0.3% 
biosynthesis 3 1042 0.3% 
cell motility 2 413 0.5% 
regulation of apoptosis 1 275 0.4% 
cell adhesion 1 651 0.2% 
amino acid metabolism 1 206 0.5% 
cell communication 3 3643 0.1% 
lipid biosynthesis 2 171 1.2% 
establishment and/or maintenance of chromatin architecture 1 209 0.5% 
BNA packaging 1 222 0.5% 
cell death 2 550 0.4% 
induction of apoptosis by p53 1 3 33.3% 
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induction of apoptosis 1 173 0.6% 
apoptosis 2 511 0.4% 
autophagy 1 4 25.0% 
cell fate determination 1 10 10.0% 
obsolete biological process 1 395 0.3% 
embryonic morphogenesis 1 11 9.1% 
organic acid metabolism 2 396 0.5% 
amino acid and d..crivative metabolism 1 254 0.4% 
embryonic development 1 30 3.3% 
ubiquitin cycJe 1 95 1.1% 
perception of sound 1 102 1.0% 
cell differentiation 2 163 1.2% 
cellular process 11 7049 0.2% 
cholesterol metabolism 1 76 1.3% 
steroid metabolism 1 153 0.7% 
response to abiotic stimulus 1 587 0.2% 
translation 1 183 0.5% 
immune cell activation 1 67 1.5% 
perception of abiotic stimulus 1 326 0.3% 
regulation of cellular process 1 439 0.2% 
perception of external stimulus 1 354 0.3% 
nucleotide-sugar metabolism 1 12 8.3% 
protein modification 2 1140 0.2% 
protein complex assembly 1 160 0.6% 
sterol biosynthesis 1 34 2.9% 
alcohol metabolism 1 226 0.4% 
sterol metabolism 1 82 1.2% 
male gamete generation 1 124 0.8% 
metabolism 19 7171 0.3% 
ceil growth and/or maintenance 9 3939 0.2% 
regulation of biological process 1 516 0.2% 
bioiogicalyrocess 28 12339 0.2% 
regulation of cell migration 1 3 33.3% 
protein folding 1 181 0.6% 
spermatogenesis 1 124 0.8% 
DNA metabolism 1 636 0.2% 
epidermal differentiation 1 79 1.3% 
cell migration 1 54 1.9% 
lymphocyte differentiation 1 26 3.8% 
hemopOiesis 1 52 1.9% 
response to biotic stimulus 2 1039 0.2% 
response to external stimulus 2 1526 0.1% 
reproduction 1 182 0.5% 
limb morphogenesis 1 3 33.3% 
gametogenesis 1 155 0.6% 
RNA metabolism ; 426 0.2% 
development 6 1956 0.3% 
carbohydrate metabolism 1 372 0.3% 
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regulation of translation 1 98 1.0% 
synaptic transmission, cholinergic 1 13 7.7% 
nerve-nerve synaptic transmission 1 15 6.7% 
thymic T-cell selection 1 3 33.3% 
transmission of nerve impulse 1 287 0.3% 
regulation of metabolism 1 58 1.7% 
UDP-N-acetylglucosamine metabolism 1 4 25.0% 
deat.t, 2 557 0.4% 
N-acetylglucosamine metabolism 1 6 16.7% 
nuclear organization and biogenesis 1 263 0.4% 
glucosamine metabolism 1 9 11.1% 
organelle organization and biogenesis 1 298 0.3% 
amino sugar metabolism 1 15 6.7% 
synaptic transmission 1 281 0.4% 
T-cell selection 1 6 16.7% 
cell-cell signaling 2 665 0.3% 
fatty acid biosynthesis 1 48 2.1% 
fatty acid metabolism 1 141 0.7% 
hair ceil differentiation i :2 50.0% 
mechanoreceptor differentiation 1 2 50.0% 
RNA processing 1 406 0.2% 
UDP-N-acetylglucosamine transport 1 2 50.0% 
intracellular transport 1 597 0.2% 
regulation of transcription 7 2131 0.3% 
cytoskeleton-dependent intracellular transport 1 39 2.6% 
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Table 6: Biological processes that are associated with genes altered by treatment 




Altered on % 
biologicalJ>rocess genes array 
regulation of JNK cascade 1 7 14.3% 
membrane fusion 1 22 4.5% 
circadian rhythm 1 20 5.0% 
rhythmic behavior 1 29 3.4% 
striated muscle contraction 1 42 2.4% 
excretion 2 55 3.6% 
frizzled-2 signaling pathway 1 17 5.9% 
phYSiological process 122 10507 1.2% 
G-PfQtein Signaling, aden)'lale cyclase activating pathway 1 41 2.4% 
G-protein signaling, coupled to cAMP nucleotide second messenger 1 95 1.1% 
G-protein signaling, coupled to cyclic nucleotide second messenger 2 140 1.4% 
G-protein coupled receptor protein signaling pathway 7 636 1.1% 
nuclear division 2 215 0.9% 
mevalonate transport 1 4 25.0% 
phospholipid biosynthesis 1 39 2.6% 
muscle contraction 4 208 1.9% 
behavior 2 109 1.8% 
neuropeptide signaling pathway 1 90 1.1% 
endocytosis 1 144 0.7% 
glutamate signaling pathway 1 19 5.3% 
sexual reproduction 3 182 1.6% 
M phase 2 218 0.9% 
mitotic cell cycle 5 448 1.1% 
serotonin receptor signaling pathway 1 4 25.0% 
nucleobase, nucleoside, nucleotide and nucleic acid metaboli.sm 37 3310 1.1% 
tricarboxylic acid cycle 1 30 3.3% 
cell motility 5 413 1.2% 
monocarboxylic acid transport 1 21 4.8% 
main pathways of carbohydrate metabolism 1 97 1.0% 
energy pathways 2 265 0.8% 
hearing 2 100 2.0% 
carbohydrate transport 1 26 3.8% 
amino acid derivative biosynthesis 1 32 3.1% 
phototransduction 1 22 4.5% 
vision 2 185 1.1% 
sensory perception 3 327 0.9% 
organic anion transport 1 43 2.3% 
ER to Golgi transport 1 28 3.6% 
exocytosis 1 55 1.8% 
intracellular protein transport 4 459 0.9% 
pregnancy 1 69 1.4% 
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di-, tri-valent inorganic cation transport 3 142 2.1% 
modification-dependent protein catabolism 1 141 0.7% 
monovalent inorganic cation transport 4 264 1.4% 
transmembrane receptor protein tyrosine kinase signaling pathway 1 137 0.7% 
RNA transport 1 38 2.6% 
nucleic acid transport 1 38 2.6% 
enzyme linked receptor protein signaling pathway 1 214 0.5% 
re.sponse to endogenous stimulus 3 274 1.1% 
cell surface receptor linked signal transduction 12 1095 1.1% 
protein amino acid glycosylation 1 115 0.9% 
signal transduction 33 2915 1.1% 
regulation of circadian sleep/wake cycle, sleep 1 3 33.3% 
response to radiation 3 217 1.4% 
organic acid metabolism 5 396 1.3% 
induction of apoptosis 1 173 0.6% 
positive regulation of programmed cell death 1 173 0.6% 
apoptosis 9 511 1.8% 
regulation of programmed cell death 1 173 0.6% 
autophagy 1 4 25.0% 
nucleocytoplasmic transport 2 136 1.5% 
positive regulation of apoptosis 1 173 0.6% 
phagocytosis, engulfment 1 12 8.3% 
amino acid and derivative metabolism 1 254 0.4% 
cyclic-nucleotide-mediated signaling 2 140 1.4% 
CAMP-mediated Signaling 1 95 1.1% 
second-messenger-mediated Signaling 2 146 1.4% 
ubiquitin-dependent protein catabolism 1 141 0.7% 
heterophilic cell adhesion 1 100 1.0% 
protein metabolism 25 2584 1.0% 
electron transport 2 365 0.5% 
homophilic cell adhesion 3 93 3.2% 
cell adhesion 8 651 1.2% 
cell communication 39 3643 1.1% 
amine biosynthesis 1 63 1.6% 
amine metabolism 3 295 1.0% 
induction of programmed cell death 1 173 0.6% 
protein secretion 1 21 4.8% 
phagocytosis 1 28 3.6% 
programmed cell death 9 512 1.8% 
DNA damage response, signal transduction 1 28 3.6% 
vesicle dOcking during the process of exocytosis 1 14 7.1% 
lipid transport 1 70 1.4% 
cell-cell adhesion 4 218 1.8% 
proteolysis and peptidolysis 7 606 1.2% 
amino acid transport 1 53 1.9% 
reguiation of ceii growth 1 76 1.2% 
ribonucleotide biosynthesis 1 68 1.5% 
protein amino acid phosphorylation .... 612 1.1% I 
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fumarate metabolism 1 3 33.3% 
protein modification 9 1140 0.8% 
protein compiex assembly 3 160 1.9% 
TeA intermediate metabolism 1 25 4.0% 
alcohol metabolism .. 226 0.4% I 
negative regulation of cell growth 1 10 10.0% 
morphogenesis 16 1210 1.3% 
biogenic amine biosynthesis 1 26 3.8% 
ribonucleotide metabolism 1 73 1.4% 
cell death 9 550 1.6% 
lipid biosynthesis 2 171 1.2% 
water -soluble vitamin biosynthesis 1 6 16.7% 
mesoderm development 2 31 6.5% 
protein folding 2 181 1.1% 
mitotic metaphase/anaphase transition 1 6 16.7% 
regulation of circadian rhythm 1 3 33.3% 
translation 1 183 0.5% 
cholesterol metabolism 1 76 1.3% 
steroid metabolism 3 153 2.0% 
proton transport 3 86 3.5% 
phosphorylation 8 648 1.2% 
regulation of translational initiation 1 49 2.0% 
regulation of translation 1 98 1.0% 
regulation of circadian sleep/wake cycle 1 .3 33.3% 
activation of MAPKKK 1 6 16.7% 
UDP-N-acetylglucosamine metabolism 1 4 25.0% 
circadian sleep/wake cycle 1 3 33.3% 
N-acetylglucosamine metabolism 1 6 16.7% 
glucosamine metabolism 1 9 11.1% 
amino sugar metabolism 1 15 6.7% 
NF-kappaB-nucieus import 1 8 12.5% 
negative regulation of NF-kappa8-nucleus import 1 7 14.3% 
regulation of NF-kappaB-nucleus import 1 8 12.5% 
muscle development 2 168 1.2% 
perception of sound 2 102 2.0% 
small molecule transport 2 66 3.0% 
energy derivation by oxidation of organic compounds 1 158 0.6% 
negative regulation of transcription, DNA-dependent 3 98 3.1% 
phosphate metabolism 8 808 1.0% 
death 9 .5.57 1.6% 
metabolism 81 7171 1.1% 
phosphorus metabolism 8 808 1.0% 
cell growth and/or maintenance 46 3939 1.2% 
biologicalyrocess 139 12339 1.1% 
mRNA processing 1 200 0.5% 
response to abiotic stimulus 4 587 0.7% 
cellular process 80 7049 1.1% 
RNA processing 2 406 0.5% 
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nucleotide-sugar metabolism 1 12 8.3% 
heart development 1 30 3.3% 
perception of iight (3 191 1.6% 
epidermal differentiation 2 79 2.5% 
perception of abiotic stimulus 4 326 1.2% 
perception of external stimulus 4 354 1.1% 
prostaglandin biosynthesis 1 11 9.1% 
anion transport 1 116 0.9% 
mitosis 2 170 1.2% 
MAP KKK cascade 1 58 1.7% 
glycosaminoglycan catabolism 1 5 20.0% 
aminoglycan catabolism 1 5 20.0% 
transcription from Pol III promoter 1 36 2.8% 
response to pest/pathogen/parasite 1 543 0.2% 
innate immune response 1 214 0.5% 
aminoglycan metabolism 1 26 3.8% 
response to wounding 1 323 0.3% 
hydrogen transport 3 86 3.5% 
vesicte docking 1 14 7.1% 
calcium ion transport 3 97 3.1% 
potaSSium ion transport 1 145 0.7% 
regulation of neurotransmitter levels 1 45 2.2% 
cation transport 6 454 1.3% 
jon transport 8 625 1.3% 
transport 22 1853 1.2% 
skeletal development 2 171 1.2% 
cytolYSiS 1 17 5.9% 
translational initiation 1 79 1.3% 
protein biosynthesis 3 565 0.5% 
chromosome segregation 3 34 8.8% 
response to biotic stimulus 12 1039 1.2% 
response to external stimulus 15 1526 1.0% 
fatty acid oxidation 1 24 4.2% 
carboxylic acid transport 2 78 2.6% 
nitrogen metabolism 1 42 2.4% 
purine ribonucleoside monophosphate biosynthesis 1 13 7.7% 
purine ribonucleoside monophosphate metabolism 1 13 7.7% 
nicotinamide metabolism 1 15 6.7% 
nucleotide biosynthesis 1 119 0.8% 
oxygen and reactive oxygen species metabolism 2 61 3.3% 
water -soluble vitamin metabolism 2 26 7.7% 
vitamin metabolism 2 35 5.7% 
ribonucleoside monophosphate metabolism 1 22 4.5% 
mRNA-nucleus export 1 31 3.2% 
RNA-nucleus export 1 38 2.6% 
RNA localization 1 38 2.6% 
cell cycle 12 872 1.4% 
oncogenesis 1 164 0.6% 
116 
transcription from Pol II promoter 11 671 1.6% 
veside-mediated transport 5 325 1.5% 
negative regulation of protein-nucieus import 1 7 14.3% 
regulation of protein-nudeus import 1 9 11.1% 
glycosaminoglycan metabolism 1 25 4.0% 
ribonucleoside monophosphate biosynthesis 1 22 4.5% 
purine ribonucleotide biosynthesis 1 58 1.7% 
protein cat..abolism 7 610 1.1% 
coenzyme and prosthetic group biosynthesis 1 82 1.2% 
purine ribonucleotide metabolism 1 63 1.6% 
neurogenesis 8 492 1.6% 
ectoderm development 2 95 2.1% 
regulation of transcription from Pol III promoter 1 9 11.1% 
regulation of transcription from Pol II promoter 9 360 2.5% 
regulation of transcription, DNA-dependent 25 2120 1.2% 
transcription, DNA-dependent 26 2262 1.1% 
transcription 26 2313 1.1% 
glycolipid catabolism 1 11 9.1% 
nucleobase, nucleoside, nucleotide and nucleic acid transport 1 47 2.1% 
cell differentiation 3 163 1.8% 
regulation of transcription 25 2131 1.2% 
peripheral nervous system development 1 12 8.3% 
siderochrome transport 2 197 1.0% 
brain development 1 34 2.9% 
negative regulation of transcription from Pol " promoter 3 81 3.7% 
secretory pathway 2 145 1.4% 
pyridine nucleotide biosynthesis 1 2 50.0% 
pyridine nucleotide metabolism 1 15 6.7% 
cytokinesis 1 113 0.9% 
male gamete generation 3 124 2.4% 
sphingolipid catabolism 1 15 6.7% 
chromatin modification 1 90 1.1% 
central nervous system development 3 120 2.5% 
oxidoreduction coenzyme metabolism 1 20 5.0% 
Golgi vesicle transport 1 72 1.4% 
coenzyme metabolism 1 100 1.0% 
coenzyme and prosthetiC group metabolism 1 120 0.8% 
nucleosome assembly 1 79 1.3% 
prostaglandin metabolism 1 23 4.3% 
prostanoid metabolism 1 23 4.3% 
carboxylic acid metabolism 5 394 1.3% 
chromatin assembly/disassembly 2 125 1.6% 
icosanoid metabolism 1 43 2.3% 
histogenesis 4 129 3.1% 
intracellular transport 6 597 1.0% 
organogenesis 14 1090 1.3% 
cytoplasmic sequestering of transcription factor 1 8 12.5% 
secretion 2 52 3.8% 
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negative regulation of transcription factor -nucleus import 1 8 12.5% 
transcription factor-oucleus import 1 9 11.1% 
regulation of transcription factor -nucleus import 1 9 11.1% 
purine nucleoside monophosphate biosynthesis 1 13 7.7% 
purine nucleoside monophosphate metabolism 1 13 7.7% 
nucleoside monophosphate biosynthesis 1 25 4.0% 
nucleoside monophosphate metabolism 1 25 4.0% 
membrane lipid biosynt'1esis 1 50 2.0% 
membrane lipid catabolism 1 19 5.3% 
negative regulation of cell cycle 2 82 24% 
glycosphingolipid metabolism 1 25 4.0% 
establishment and/or maintenance of chromatin architecture 2 209 1.0% 
telomere binding 1 1 100.0% 
DNA packaging 2 222 0.9% 
chromosome organization and biogenesis (sensu Eukarya) 2 256 0.8% 
regulation of apoptosis 1 275 04% 
DNA repair 3 236 1.3% 
nucleotide metabolism 1 159 0.6% 
vitamin biosynthesis 1 6 16.7% 
prostanoid biosynthesis 1 11 9.1% 
icosanoid biosynthesis 1 26 3.8% 
mitotic anaphase 1 23 4.3% 
DNA recombination 1 86 1.2% 
coenzyme biosynthesis 1 65 1 .. 5% 
M phase of mitotic cell cycle 2 171 1.2% 
G2/M transition of mitotic cell cycle 2 69 2.9% 
steroid catabolism 1 12 8.3% 
glycoprotein biosynthesis 1 120 0.8% 
8 phase of mitotic cell cycle 3 180 1.7% 
glycoprotein metabolism i 134 0.7% 
G 1/8 transition of mitotic cell cycle 1 83 1.2% 
sphingolipid metabolism 1 44 2.3% 
glycolipid metabolism 1 30 3.3% 
regulation of behavior 1 3 33.3% 
regulation of ~l!.Jlar prPCess 5 439 1.1% 
regulation of enzyme activity 1 80 1.3% 
DNA dependent DNA replication 1 87 1.1% 
DNA replication 2 177 1.1% 
regulation of CDK activity 1 53 1.9% 
organic acid transport 2 78 2.6% 
DNA damage response, signal transduction resulting in cell cycle arrest 1 20 5.0% 
cell cycle checkpoint 1 55 1.8% 
macromolecule biosynthesis 6 885 0.7% 
regulation of cell cycle 6 505 1.2% 
biosynthesis 8 1042 0.8% 
macromolecule catabolism 7 &is 1.1% 
catabolism 10 873 1.1% 
mitotic chromosome segregation 1 15 6.7% 
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regulation of heart rate 1 34 2.9% 
circulation 2 134 1.5% 
sterol metabolism 1 82 1.2% 
carbohydrate metabolism 3 372 0.8% 
obsolete biological process 4 395 1.0% 
GMP metabolism 1 3 33.3% 
negative regulation of transcription 3 117 2.6% 
regulation of biological process 7 516 1.4% 
carboxylic acid biosynthesis 1 56 1.8% 
DNA metabolism 7 636 1.1% 
nicotinamide adenine dinucleotide metabolism 1 2 50.0% 
negative regulation of nucleocytoplasmic transport 1 7 14.3% 
DNA replication and chromosome cycle 5 226 2.2% 
regulation of nucleocytoplasmic transport 1 9 11.1% 
amine/polyamine transport 1 58 1.7% 
glycolate metabolism 1 4 25.0% 
coagulation 2 111 1.8% 
phospholipid metabolism 1 75 1.3% 
membrane lipid metabolism 2 123 1.6% 
spermatid development 1 6 16.7% 
spermatogenesis 3 124 2.4% 
mRNA metabolism 1 212 0.5% 
RNA metabolism 2 428 0.5% 
protein transport 4 486 0.8% 
carnitine metaboiism ; 1 100.0% 
nicotinamide adenine dinucleotide biosynthesis 1 2 50.0% 
UDP-N-acetylglucosamine transport 1 2 50.0% 
nuclear organization and biogenesis 2 263 0.8% 
fatty acid beta-oxidation 1 22 4.5% 
fatty acid biosyml1esis 1 48 2.1% 
circadian sleep/wake cycle, sleep 1 3 33.3% 
pyrimidine nucleotide-sugar transport 1 5 20.0% 
fatty acid metabolism 2 141 1.4% 
nucleotide-sugar transport 1 5 20.0% 
gametogenesis 3 155 1.9% 
development 26 1956 1.4% 
synaptic transmission, cholinergic 1 13 7.7% 
nerve-nerve synaptic transmission 1 15 6.7% 
sleep 1 4 25.0% 
lipid metabolism 8 578 1.4% 
carnitine biosynthesis 1 1 100.0% 
neurotransmitter secretion 1 23 4.3% 
synaptic transmission 6 281 2.1% 
cell-cell signaling 9 665 1.4% 
RAS protein signal transduction 2 50 4.0% 
small GTPase mediated signal transduction 4 275 1.5% 
Wnt receptor signaling pathway 1 39 2.6% 
organic acid biosynthesis 1 56 1.8% 
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carbohydrate catabolism 1 67 1.5% 
response to light 3 198 1.5% 
regulation of cell proliferation 4 366 1.1% 
response to oxidative stress 2 44 4.5% 
response to DNA damage stimulus " 274 1.1% .;) 
cell growth 1 96 1.0% 
activation of JUNK 2 12 16.7% 
grQ\¥th 1 33 3.0% 
biogenic amine metabolism 1 50 2.0% 
amino acid derivative metabolism 1 59 1.7% 
JNKcascade 3 45 6.7% 
cytoplasmic sequestering of NF-kappaB 1 7 14.3% 
cell organization and biogenesis 2 632 0.3% 
lipid catabolism 2 81 2.5% 
activation of NF-kappaB-inducing kinase 1 12 8.3% 
GMP biosynthesis 1 " 33.3% .;) 
protein-nucleus import 1 90 1.1% 
protein targeting 2 173 1.2% 
NJK-I-kappaBINF~ppaB casaade 3 28 10.7% 
negative regulation of cell proliferation 1 201 0.5% 
positive regulation of cell proliferation 3 165 1.8% 
cell proliferation 18 1341 1.3% 
reproduction 3 182 1.6% 
protein kinase cascade 6 197 3.0% 
intracellular signaling cascade 13 1102 1.2% 
transmission of nerve impulse 6 287 2.1% 
purine nucleotide biosynthesis 1 62 1.6% 
purine nucleotide metabolism 1 70 1.4% 
immune response 9 903 1.0% 
inflammatory response 1 211 0.5% 
defense response 10 963 1.0% 
hemostasis 3 120 2.5% 
feeding behavior 1 24 4.2% 
metal ion transport 4 351 1.1% 
response to stres.s 10 972 1.0% 
blood coagulation 2 111 1.8% 
adenylate cyclase activation 1 38 2.6% 
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Figure 19: 2D separation of cytoplasmic proteins from cells treated with GRO, 
CltO or lett untreated. 
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Oligonucleotide therapeutics are an emerging class of drugs that are gaining 
interest due to their apparent high target specitIcity and few toxic side effects. Therapy 
utilizing oligonucleotides is now being developed as treatment in a variety of diseases 
including cancer, genetic disorders, coronary disease, and HIV [1-4]. The strategies used 
by oligonucleotides inc1ude triplex formation (which targets DNA), antisense (which 
targets RNA), siRNA (which targets RNA), and aptamer (which involve target proteins 
and shape recognition) [5-13]. 
An oligonucleotide therapy thought to function using the aptamer mechanism is 
guanine-rich oligonucleotides (GROs). GROs are now being investigated as a new 
therapeutic against cancer, viral diseases, and other i11nesses. tl:tU]S are capable of 
forming the secondary structure known as a G-quartet. G-quartets contain four coplanar 
guanines stabilized by Hoogsteen hydrogen bonds. These G-quartets are capable of 
stacking upon one another which increases the stabitity of the structure. Sequences 
capable of forming G-quartets have been identified throughout nature including the c-myc 
promoter, the fragile X repeat, and mVl RNA [14-19, 22-28, 30-33, 149]. 
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GROs exhibit potent antiproliferative properties against several cancer cell lines 
[34-31], and demonstrated the same anticancer effects in an in vivo tumor mouse model 
(Figure 6D). Phase I clinical trials have also demonstrated that GROs could be a 
promising clinical agent against cancer [38]. The antiproliferative activity of GROs 
apparently has a novel mechanism of action, although some aspects of its function have 
previously been shown. Upon treatment with GRO, cancer cells undergo S phase cell 
cycle arrest, DNA replication inhibition, and cell death [35]. It has also been shown that 
the activity of tl"K.Os requires the formation of tl-quartets, but the secondary structure 
alone cannot predict the antiprolifurative activity of GRO. The only predictive factor was 
the GROs' ability to bind to complex of proteins, one of which has been identified as 
nuc1eotin which has been identified as the primary target of tl"K.Os [34, 31]' tl"K.Os couid 
exhibit their antiproliferative effects by either modifying the function of nucleolin 
directly or GROs could bind to nucleolin on the surface of the cell which shuttles the 
tl"K. 0 inside the celt where the functions of proteins other than nuc1eoHn are affected. 
To gain insight into the mechanism of GROs, we first identified the proteins that 
bind to an active tl"K.O by utitizing biotynlated oHonuc1eotides for precipitation and mass 
spectrometry for the identification of the bound proteins. In Chapter II, I identified 14 
nuclear proteins and 3 cytoplasmic proteins that are able to bind to an active GRO but not 
able to bind to an inactive tl"K.O (see Table 2 for comptete tist). Nuc1eoiin was identified 
as a GRO-binding protein, validating the technique. The functions of the additional 
proteins are diverse; however, several of their functions correlate with functions of 
nuc1eotin. These inc1ude apoptosis, ribosome assemb1y, ONA repair, rRNA maturation, 
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and nucleocytoplasmic transport. Furthennore, several identified proteins have 
previously been shown to have the abitity to bind to nuc1eotin. 't'his data supports that 
nucleolin is the primary target of GROs, and an important aspect of the mechanism of 
GROs is modifying the function of nucleolin. 
One important GRO-binrung protein identifIed in Chapter 11 is NEMO (NF-Kl3 
essential modulator). I chose to further investigate the possible role of NEMO in the 
mechanism of GRO antiproliferative activity because of its important role in NF-Kl3 
signaling. NF-KB is often deregulated in cancer cells [135, 136], and it was previously 
reported that NF-KB transcription is inhibited by polyguanine oligonucelotides [137]. As 
seen in Chapter III, I report here that GROs do inhibit NF-KB transcription. I show that 
GROs bind to NEMO, inhibit the activation of the IKK complex, and inhibit the 
phoshphorylation ofIKBa.. I also show that when cells are treated with the GRO, NEMO 
and nucleolin co-precipitate. Because nucleolin is the primary target of GROs, the co-
precipiation of the nucleolin-NEMO complex suggests nucleohn may playa role in NF-
KB transcription (which is further investigated in Chapter IV). 
For further insight into the mechanism of GRO antiproliferative activity, we 
assessed the global gene and protein expression in cells treated with an active GRO 
compared to untreated ce11s and ce11s treated with an inactive tlKt). This was achieved 
by utilizing recent advances in global expression technology with microarray and 2D 
electrophoresis; the results are reported in Chapter V. Although the global protein 
expression analysis did not revea1 any changes (see P'igures 18 and 1 ~), the global gene 
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expression data revealed the alteration of many genes when a cell is treated with the 
GR<:J, as seen in 'fables 3 and 4. The analysis revea1ed 63 genes changed after 2 h of 
treatment with the GRO, and 238 genes changed after 18 h of treatment. The expression 
of nucleolin was not changed. suggesting that GROs do not apparently affect the 
transcription of nucleoHn. the dRO-a1tered genes are involved in several different 
cellular processes (see Tables 5 and 6) including transcription, transport, apoptosis, cell 
motility, and regulation of cell growth. Interestingly, some of the same cellular functions 
that are affected by GR<:Js have been imp1icated in the function of nudeoHn, which is 
consistent with our hypothesis that GROs exert their activity by modifying the function 
of nucleolin. 
The data presented in this dissertation is consistent with our functional model 
which is represented by the schematic in Figure 20. Nucleolin that is present on the 
surface of cancer ceUs binds to the GRO which mediates its uptake into the ce11. Upon 
internalization, the GRO interferes with molecular interactions of nucleolin and other 
proteins in the nucleus, cytoplasm, and plasma membrane. The alteration of these 
nuc1eoHn-protein interactions leads to antiprotiferative effects induding ce11 cyc1e arrest, 
inactivation of NF-KB, and induction of cell death. The selectivity of (iRO comes from 
the presence of nucleolin on the surface of cancer cells. Nucleolin is absent on the 
surface of norma1 ceUs, thus preventing the uptake of GR<:J and 1eaving the ce11 
unaffected. 
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Figure 20: Proposed model for GRO mechanism. 
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FIGURE 17: Proposed Model for GRO Mechanism 
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In conclusion, more work is needed to decipher the precise molecular mechanism 
of the antiproiiterative activity of GROs. However, in the present study, important new 
insights into the mechanism have been revealed. All of the data presented here supports 
the hypothesis that GROs bind primarily to nucleolin, and modulate the normal function 
of nuc1eoiin. A1though the detaited mechanism of GROs was not e1ucidated in this study, 
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